Tavneos

Overview

avacopan

complement inhibitor

• CYP3A4 substrate
• CYP3A4 inhibitor, moderate
• immunomodulatory effects

Contraindicated

• BCG live intravesical
Tavneos (avacopan)

+

BCG live intravesical

2 interactions

Contraindicated

avacopan + BCG live intravesical

contraindicated: combo may incr. risk of disseminated BCG infection; may decr. immune response (immunosuppressive effects)

• lomitapide
Tavneos (avacopan)

+

lomitapide

1 interaction

Contraindicated

avacopan + lomitapide

contraindicated: combo may incr. lomitapide levels, risk of hepatotoxicity, other adverse effects (hepatic metabolism inhibited)

Avoid/Use Alternative

• alprazolam
Tavneos (avacopan)

+

alprazolam

2 interactions

Avoid/Use Alternative

avacopan + alprazolam

use alternative or monitor respiratory rate; consider decr. alprazolam dose: combo may incr. alprazolam levels, risk of CNS and respiratory depression, psychomotor impairment, other adverse effects (hepatic metabolism inhibited)

• apalutamide
Tavneos (avacopan)

+

apalutamide

2 interactions

Avoid/Use Alternative

avacopan + apalutamide

avoid combo: combo may decr. avacopan levels, efficacy (hepatic metabolism induced)

• aprepitant
Tavneos (avacopan)

+

aprepitant

1 interaction

Avoid/Use Alternative

avacopan + aprepitant

avoid combo w/ oral aprepitant; IV aprepitant use OK: combo may incr. levels of both drugs, risk of adverse effects (hepatic metabolism inhibited)

• bosentan
Tavneos (avacopan)

+

bosentan

1 interaction

Avoid/Use Alternative

avacopan + bosentan

avoid combo: combo may incr. bosentan levels, risk of adverse effects; may decr. avacopan levels, efficacy (hepatic metabolism inhibited; hepatic metabolism induced)

• brigatinib
Tavneos (avacopan)

+

brigatinib

1 interaction

Avoid/Use Alternative

avacopan + brigatinib

use alternative or monitor BP, HR; decr. brigatinib dose by approx. 40% as follows: if taking 180 mg, decr. to 120 mg, if taking 120 mg, decr. to 90 mg; if taking 90 mg, decr. to 60 mg: combo may incr. brigatinib levels, risk of HTN, bradycardia, other adverse effects; may decr. avacopan levels, efficacy (hepatic metabolism inhibited; hepatic metabolism induced)

• butalbital
Tavneos (avacopan)

+

butalbital

1 interaction

Avoid/Use Alternative

avacopan + butalbital

avoid combo: combo may decr. avacopan levels, efficacy (hepatic metabolism induced)

• cariprazine
Tavneos (avacopan)

+

cariprazine

1 interaction

Avoid/Use Alternative

avacopan + cariprazine

IF STARTING CARIPRAZINE TX: ADULT PTS: adjust dose as follows: SCHIZOPHRENIA/BIPOLAR MANIA: start cariprazine 0.75 mg qd, then may incr. to 1.5 mg qd; BIPOLAR DEPRESSION/DEPRESSION ADJUNCT: start cariprazine 0.75 mg qd; PEDS PTS: avoid combo; IF ON STABLE CARIPRAZINE TX AND STARTING AVACOPAN: ADULT AND PEDS PTS, ALL INDICATIONS: adjust cariprazine dose as follows: if on cariprazine 1.5 mg or 3 mg qd, decr. dose to 0.75 mg qd; if on cariprazine 4.5 mg or 6 mg qd, decr. dose to 1.5 mg qd: combo may incr. cariprazine and active metabolite levels, risk of adverse effects (hepatic metabolism inhibited)

• cladribine oral
Tavneos (avacopan)

+

cladribine oral

2 interactions

Avoid/Use Alternative

avacopan + cladribine oral

avoid combo: combo may incr. risk of serious infection (additive effects)

• codeine
Tavneos (avacopan)

+

codeine

2 interactions

Avoid/Use Alternative

avacopan + codeine

use alternative or monitor respiratory rate, consider decr. codeine dose: combo may incr. codeine and active metabolite morphine levels, risk of CNS and respiratory depression, psychomotor impairment, other adverse effects (hepatic metabolism inhibited, may incr. production of active metabolite morphine)

• colchicine
Tavneos (avacopan)

+

colchicine

1 interaction

Avoid/Use Alternative

avacopan + colchicine

CV RISK REDUCTION: avoid combo in pts w/ renal or hepatic impairment; otherwise, monitor CK, myopathy s/sx; GOUT or FMF: use alternative or decr. colchicine dose based on indication during and x14 days after avacopan use as follows: GOUT PROPHYLAXIS: give colchicine 0.3-0.6 mg/day divided qd-bid; ACUTE GOUT TX: avoid combo if already receiving colchicine for gout prophylaxis; otherwise, give colchicine 1.2 mg x1 only; FMF: decr. max colchicine dose to 1.2 mg/day divided qd-bid: combo may incr. colchicine levels, risk of myopathy, rhabdomyolysis, other life-threatening toxicity (hepatic metabolism inhibited)

• dabrafenib
Tavneos (avacopan)

+

dabrafenib

1 interaction

Avoid/Use Alternative

avacopan + dabrafenib

avoid combo: combo may decr. avacopan levels, efficacy (hepatic metabolism induced)

• dihydrocodeine
Tavneos (avacopan)

+

dihydrocodeine

1 interaction

Avoid/Use Alternative

avacopan + dihydrocodeine

use alternative or monitor respiratory rate, consider decr. dihydrocodeine dose: combo may incr. dihydrocodeine and active metabolite dihydromorphine levels, risk of CNS and respiratory depression, psychomotor impairment, other adverse effects (hepatic metabolism inhibited)

• disopyramide
Tavneos (avacopan)

+

disopyramide

1 interaction

Avoid/Use Alternative

avacopan + disopyramide

use alternative or monitor disopyramide levels, ECG: combo may incr. disopyramide levels, risk of QT prolongation, cardiac arrhythmias, other adverse effects (hepatic metabolism inhibited)

• dordaviprone
Tavneos (avacopan)

+

dordaviprone

1 interaction

Avoid/Use Alternative

avacopan + dordaviprone

use alternative or monitor ECG; for adult and pediatric pts weighing at least 52.5 kg, decr. dordaviprone dose to 500 mg once weekly; dose recommendation not established in pediatric pts weighing less than 52.5 kg: combo may incr. dordaviprone levels, risk of QT prolongation, cardiac arrhythmias, other adverse effects (hepatic metabolism inhibited)

• efavirenz
Tavneos (avacopan)

+

efavirenz

1 interaction

Avoid/Use Alternative

avacopan + efavirenz

avoid combo: combo may decr. avacopan levels, efficacy (hepatic metabolism induced)

• elagolix
Tavneos (avacopan)

+

elagolix

2 interactions

Avoid/Use Alternative

avacopan + elagolix

avoid combo if elagolix 300 mg bid regimen; otherwise, caution advised: combo may decr. avacopan levels, efficacy (hepatic metabolism induced)

• encorafenib
Tavneos (avacopan)

+

encorafenib

1 interaction

Avoid/Use Alternative

avacopan + encorafenib

avoid combo: combo may incr. encorafenib levels, risk of QT prolongation, cardiac arrhythmias, other adverse effects; may decr. avacopan levels, efficacy (hepatic metabolism inhibited; hepatic metabolism induced)

• ensartinib
Tavneos (avacopan)

+

ensartinib

2 interactions

Avoid/Use Alternative

avacopan + ensartinib

avoid combo: combo may incr. ensartinib levels, risk of bradycardia, hyperglycemia, other adverse effects (hepatic metabolism possibly inhibited)

• entrectinib
Tavneos (avacopan)

+

entrectinib

1 interaction

Avoid/Use Alternative

avacopan + entrectinib

PEDS PTS w/ ENTRECTINIB START DOSE <200 mg/day: avoid combo; ADULT AND PEDS PTS >2yo: use alternative or monitor ECG, CBC, limit coadmin. to 14 days or less and decr. entrectinib dose as follows: if entrectinib start dose 200 mg qd, decr. to 50 mg qd; if entrectinib start dose 300 mg qd, decr. to 100 mg qd; if entrectinib start dose 400 or 600 mg qd, decr. to 200 mg qd: combo may incr. entrectinib levels, risk of QT prolongation, cardiac arrhythmias, myelosuppression, other adverse effects (hepatic metabolism inhibited)

• ergotamine
Tavneos (avacopan)

+

ergotamine

1 interaction

Avoid/Use Alternative

avacopan + ergotamine

use alternative: combo may incr. ergotamine levels, risk of ergot toxicity, severe vasospasm, ischemia, other adverse effects (hepatic metabolism inhibited)

• etravirine
Tavneos (avacopan)

+

etravirine

1 interaction

Avoid/Use Alternative

avacopan + etravirine

avoid combo: combo may decr. avacopan levels, efficacy (hepatic metabolism induced)

• fexinidazole
Tavneos (avacopan)

+

fexinidazole

1 interaction

Avoid/Use Alternative

avacopan + fexinidazole

avoid combo: combo may decr. avacopan levels, efficacy; may decr. fexinidazole active metabolite levels, efficacy (hepatic metabolism induced; hepatic metabolism inhibited, decr. conversion to active metabolites)

• fosphenytoin
Tavneos (avacopan)

+

fosphenytoin

2 interactions

Avoid/Use Alternative

avacopan + fosphenytoin

avoid combo: combo may decr. avacopan levels, efficacy (hepatic metabolism induced)

• hydrocodone
Tavneos (avacopan)

+

hydrocodone

2 interactions

Avoid/Use Alternative

avacopan + hydrocodone

use alternative or monitor respiratory rate, ECG, consider decr. (benz)hydrocodone dose: combo may incr. hydrocodone levels, risk of CNS and respiratory depression, psychomotor impairment, QT prolongation, cardiac arrhythmias, other adverse effects (hepatic metabolism inhibited)

• iberdomide
Tavneos (avacopan)

+

iberdomide

1 interaction

Avoid/Use Alternative

avacopan + iberdomide

use alternative or decr. iberdomide dose to 0.75 mg qd on Days 1 to 21 of a 28-day cycle; if further dose modification needed due to adverse events, decr. iberdomide dose to 1 mg every other day on Days 1 to 21 of a 28-day cycle: combo may incr. iberdomide levels, risk of serious infection, myelosuppression, thromboembolism, other adverse effects (hepatic metabolism inhibited, additive effects)

• ivacaftor
Tavneos (avacopan)

+

ivacaftor

1 interaction

Avoid/Use Alternative

avacopan + ivacaftor

pts <6 mo: avoid combo; pts >6 mo decr. ivacaftor dose as follows: 6 mo-5 yo and 5-6.9 kg: give 25 mg qd; 6 mo-5 yo and 7-13.9 kg: give 50 mg qd; 6 mo-5 yo and >14 kg: give 75 mg qd; 6 yo and older: give 150 mg qd: combo may incr. ivacaftor levels, risk of adverse effects (hepatic metabolism inhibited)

• ixabepilone
Tavneos (avacopan)

+

ixabepilone

1 interaction

Avoid/Use Alternative

avacopan + ixabepilone

consider alternative or monitor CBC: combo may incr. ixabepilone levels, risk of serious infection, myelosuppression, other adverse effects (hepatic metabolism inhibited, additive effects)

• levoketoconazole
Tavneos (avacopan)

+

levoketoconazole

2 interactions

Avoid/Use Alternative

avacopan + levoketoconazole

consider alternative x2wk before and during levoketoconazole tx; otherwise, monitor ECG, decr. avacopan dose to 30 mg qd: combo may incr. levels of both drugs, risk of QT prolongation, cardiac arrhythmias, other adverse effects (hepatic metabolism inhibited)

• lonafarnib
Tavneos (avacopan)

+

lonafarnib

1 interaction

Avoid/Use Alternative

avacopan + lonafarnib

consider alternative or monitor HR, ECG, electrolytes, especially during first week when adding lonafarnib to existing avacopan tx; decr. avacopan dose to 30 mg qd: combo may incr. levels of both drugs, risk of QT prolongation, cardiac arrhythmias, other adverse effects (hepatic metabolism inhibited)

• lumacaftor/ivacaftor
Tavneos (avacopan)

+

lumacaftor/ ivacaftor

2 interactions

Avoid/Use Alternative

avacopan + lumacaftor/ ivacaftor

avoid combo: combo may incr. ivacaftor levels, risk of adverse effects; may decr. avacopan levels, efficacy (hepatic metabolism inhibited; hepatic metabolism induced)

• lurbinectedin
Tavneos (avacopan)

+

lurbinectedin

2 interactions

Avoid/Use Alternative

avacopan + lurbinectedin

use alternative or monitor CBC; decr. lurbinectedin dose 50%: combo may incr. lurbinectedin levels, risk of myelosuppression, other adverse effects (hepatic metabolism inhibited)

• macitentan
Tavneos (avacopan)

+

macitentan

2 interactions

Avoid/Use Alternative

avacopan + macitentan

if also combined w/ strong-mod CYP2C9 inhibitor, avoid combo; otherwise, caution advised: combo may incr. macitentan levels, risk of adverse effects (hepatic metabolism inhibited)

• mavacamten
Tavneos (avacopan)

+

mavacamten

2 interactions

Avoid/Use Alternative

avacopan + mavacamten

avoid combo: combo may incr. mavacamten levels, risk of heart failure, other adverse effects; may decr. avacopan levels, efficacy (hepatic metabolism inhibited; hepatic metabolism induced)

• meperidine
Tavneos (avacopan)

+

meperidine

2 interactions

Avoid/Use Alternative

avacopan + meperidine

use alternative or monitor respiratory rate, ECG; consider decr. meperidine dose: combo may incr. meperidine levels, risk of CNS and respiratory depression, psychomotor impairment, QT prolongation, cardiac arrhythmias, other adverse effects (hepatic metabolism inhibited)

• methadone
Tavneos (avacopan)

+

methadone

1 interaction

Avoid/Use Alternative

avacopan + methadone

use alternative or monitor respiratory rate, ECG, consider decr. methadone dose: combo may incr. methadone levels, risk of CNS and respiratory depression, psychomotor impairment, QT prolongation, cardiac arrhythmias, other adverse effects (hepatic metabolism inhibited)

• methylergonovine
Tavneos (avacopan)

+

methylergonovine

1 interaction

Avoid/Use Alternative

avacopan + methylergonovine

avoid combo: combo may incr. methylergonovine levels, risk of ergot toxicity, severe vasospasm, ischemia, other adverse effects (hepatic metabolism inhibited)

• mitapivat
Tavneos (avacopan)

+

mitapivat

2 interactions

Avoid/Use Alternative

avacopan + mitapivat

avoid combo: combo may incr. mitapivat levels, risk of adverse effects; may decr. avacopan levels, efficacy (hepatic metabolism inhibited; hepatic metabolism induced)

• mitotane
Tavneos (avacopan)

+

mitotane

1 interaction

Avoid/Use Alternative

avacopan + mitotane

avoid combo: combo may decr. avacopan levels, efficacy (hepatic metabolism induced)

• modafinil
Tavneos (avacopan)

+

modafinil

1 interaction

Avoid/Use Alternative

avacopan + modafinil

avoid combo: combo may decr. avacopan levels, efficacy (hepatic metabolism induced)

• naloxegol
Tavneos (avacopan)

+

naloxegol

1 interaction

Avoid/Use Alternative

avacopan + naloxegol

use alternative or decr. naloxegol dose to 12.5 mg/day: combo may incr. naloxegol levels, risk of adverse effects (hepatic metabolism inhibited)

• neratinib
Tavneos (avacopan)

+

neratinib

1 interaction

Avoid/Use Alternative

avacopan + neratinib

avoid combo if also combined w/ P-gp inhibitor; otherwise, caution advised: combo may incr. neratinib levels, risk of adverse effects (hepatic metabolism inhibited)

• nirogacestat
Tavneos (avacopan)

+

nirogacestat

1 interaction

Avoid/Use Alternative

avacopan + nirogacestat

avoid combo: combo may incr. levels of both drugs, risk of hypophosphatemia, other adverse effects (hepatic metabolism inhibited)

• olaparib
Tavneos (avacopan)

+

olaparib

1 interaction

Avoid/Use Alternative

avacopan + olaparib

use alternative or monitor CBC; decr. olaparib dose to 150 mg bid: combo may incr. olaparib levels, risk of myelosuppression, other adverse effects (hepatic metabolism inhibited)

• oxycodone
Tavneos (avacopan)

+

oxycodone

1 interaction

Avoid/Use Alternative

avacopan + oxycodone

use alternative or monitor respiratory rate; consider decr. oxycodone dose: combo may incr. oxycodone levels, risk of CNS and respiratory depression, psychomotor impairment, other adverse effects (hepatic metabolism inhibited)

• palovarotene
Tavneos (avacopan)

+

palovarotene

1 interaction

Avoid/Use Alternative

avacopan + palovarotene

use alternative or decr. palovarotene dose as follows: wt 10-19.9 kg maint. dose 1 mg daily, flare dose 5 mg daily wk 1-4, then 2.5 mg daily wk 5-12; wt 20-39.9 kg maint. dose 1.5 mg daily, flare dose 6 mg daily wk 1-4, then 3 mg daily wk 5-12; wt 40-59.9 kg maint. dose 2 mg daily, flare dose 7.5 mg daily wk 1-4, then 4 mg daily wk 5-12; wt 60 kg and greater or 14 yo and older maint. dose 2.5 mg daily, flare dose 10 mg daily wk 1-4, then 5 mg daily wk 5-12: combo may incr. palovarotene levels, risk of adverse effects (hepatic metabolism inhibited)

• pentobarbital
Tavneos (avacopan)

+

pentobarbital

1 interaction

Avoid/Use Alternative

avacopan + pentobarbital

avoid combo: combo may decr. avacopan levels, efficacy (hepatic metabolism induced)

• phenobarbital
Tavneos (avacopan)

+

phenobarbital

1 interaction

Avoid/Use Alternative

avacopan + phenobarbital

avoid combo: combo may decr. avacopan levels, efficacy (hepatic metabolism induced)

• pimecrolimus topical
Tavneos (avacopan)

+

pimecrolimus topical

1 interaction

Avoid/Use Alternative

avacopan + pimecrolimus topical

avoid combo: combo may incr. risk of serious infection (additive effects)

• pralsetinib
Tavneos (avacopan)

+

pralsetinib

1 interaction

Avoid/Use Alternative

avacopan + pralsetinib

use alternative or consider monitoring ECG, electrolytes and decr. pralsetinib dose as follows: if on pralsetinib 400 mg qd, decr. to 300 mg qd; if on pralsetinib 300 mg qd, decr. to 200 mg qd; if on pralsetinib 200 mg qd, decr. to 100 mg qd: combo may incr. pralsetinib levels, risk of QT prolongation, cardiac arrhythmias, other adverse effects (hepatic metabolism inhibited)

• propafenone
Tavneos (avacopan)

+

propafenone

1 interaction

Avoid/Use Alternative

avacopan + propafenone

if CYP2D6 poor metabolizer or if also combined w/ CYP2D6 inhibitor, avoid combo; otherwise, monitor ECG, BP: combo may incr. propafenone levels, risk of QT prolongation, cardiac arrhythmias, hypotension, other adverse effects (hepatic metabolism inhibited)

• repotrectinib
Tavneos (avacopan)

+

repotrectinib

1 interaction

Avoid/Use Alternative

avacopan + repotrectinib

avoid combo: combo may incr. repotrectinib levels, risk of adverse effects; may decr. avacopan levels, efficacy (hepatic metabolism inhibited; hepatic metabolism induced)

• rifabutin
Tavneos (avacopan)

+

rifabutin

1 interaction

Avoid/Use Alternative

avacopan + rifabutin

avoid combo: combo may incr. rifabutin levels, risk of myelosuppression, uveitis, other adverse effects; may decr. avacopan levels, efficacy (hepatic metabolism inhibited; hepatic metabolism induced)

• rifampin
Tavneos (avacopan)

+

rifampin

2 interactions

Avoid/Use Alternative

avacopan + rifampin

avoid combo: combo may decr. avacopan levels, efficacy (hepatic metabolism induced)

• rifapentine
Tavneos (avacopan)

+

rifapentine

1 interaction

Avoid/Use Alternative

avacopan + rifapentine

avoid combo: combo may decr. avacopan levels, efficacy (hepatic metabolism induced)

• rilzabrutinib
Tavneos (avacopan)

+

rilzabrutinib

1 interaction

Avoid/Use Alternative

avacopan + rilzabrutinib

avoid combo if avacopan use greater than 7 days; use alternative or hold rilzabrutinib if avacopan use less than 7 days: combo may incr. levels of both drugs, risk of serious infection, other adverse effects (hepatic metabolism inhibited, additive effects)

• rivaroxaban
Tavneos (avacopan)

+

rivaroxaban

2 interactions

Avoid/Use Alternative

avacopan + rivaroxaban

use alternative if CrCl <80 and combined w/ P-gp inhibitor; otherwise, monitor bleeding s/sx: combo may incr. rivaroxaban levels, risk of bleeding, other adverse effects (hepatic metabolism inhibited)

• selpercatinib
Tavneos (avacopan)

+

selpercatinib

1 interaction

Avoid/Use Alternative

avacopan + selpercatinib

use alternative or monitor ECG, electrolytes; decr. selpercatinib dose as follows: if on selpercatinib 40 mg tid, decr. to 40 mg qd; if on selpercatinib 80 mg bid, decr. to 40 mg bid; if on selpercatinib 120 mg bid, decr. to 80 mg bid; if on selpercatinib 160 mg bid, decr. to 120 mg bid: combo may incr. selpercatinib levels, risk of QT prolongation, cardiac arrhythmias, other adverse effects (hepatic metabolism inhibited)

• selumetinib
Tavneos (avacopan)

+

selumetinib

1 interaction

Avoid/Use Alternative

avacopan + selumetinib

use alternative or monitor LVEF, CK, myopathy sx; decr. selumetinib dose as follows: if on selumetinib 25 mg/m^2 bid, decr. to 20 mg/m^2 bid; if on selumetinib 20 mg/m^2 bid, decr. to 15 mg/m^2 bid; see selumetinib pkg insert for specific dose adjustments: combo may incr. selumetinib levels, risk of cardiotoxicity, myopathy, rhabdomyolysis, other adverse effects (hepatic metabolism inhibited)

• simvastatin
Tavneos (avacopan)

+

simvastatin

2 interactions

Avoid/Use Alternative

avacopan + simvastatin

use alternative or monitor CK, myopathy sx; adjust max simvastatin dose to 10 mg/day; for pts previously tolerating 80 mg/day w/o muscle toxicity x12mo, adjust max simvastatin dose to 20 mg/day: combo may incr. simvastatin levels, risk of myopathy, rhabdomyolysis, other adverse effects (hepatic metabolism inhibited)

• sonidegib
Tavneos (avacopan)

+

sonidegib

1 interaction

Avoid/Use Alternative

avacopan + sonidegib

if avacopan use 14 days or longer, avoid combo; if avacopan use <14 days, use alternative or monitor CK, myopathy symptoms: combo may incr. sonidegib levels, risk of myopathy, rhabdomyolysis, other adverse effects (hepatic metabolism inhibited)

• sonrotoclax
Tavneos (avacopan)

+

sonrotoclax

2 interactions

Avoid/Use Alternative

avacopan + sonrotoclax

consider alternative or during sonrotoclax ramp-up phase, avoid combo if sonrotoclax dose 1 mg or 2 mg/day; otherwise, decr. sonrotoclax ramp-up dose as follows: if taking 5 mg/day decr. to 1 mg/day, if 10 mg/day decr. to 2 mg/day, if 20 mg/day decr. to 5 mg/day, if 40 mg/day decr. to 10 mg/day, if 80 mg/day decr. to 20 mg/day, if 160 mg/day decr. to 40 mg/day, if 320mg/day decr. to 80 mg/day; if on stable sonrotoclax tx, decr. sonrotoclax dose to 80 mg/day; resume prior sonrotoclax dose at least 5 days after avacopan D/C: combo may incr. sonrotoclax levels, risk of serious infection, myelosuppression, tumor lysis syndrome, other adverse effects (hepatic metabolism inhibited, additive effects)

• sotorasib
Tavneos (avacopan)

+

sotorasib

2 interactions

Avoid/Use Alternative

avacopan + sotorasib

avoid combo: combo may decr. avacopan levels, efficacy (hepatic metabolism induced)

• St. John's wort
Tavneos (avacopan)

+

St. John's wort

1 interaction

Avoid/Use Alternative

avacopan + St. John's wort

avoid combo: combo may decr. avacopan levels, efficacy (hepatic metabolism induced)

• sufentanil
Tavneos (avacopan)

+

sufentanil

2 interactions

Avoid/Use Alternative

avacopan + sufentanil

consider alternative or monitor respiratory rate, consider decr. sufentanil dose or frequency: combo may incr. sufentanil levels, risk of CNS and respiratory depression, psychomotor impairment, other adverse effects (hepatic metabolism inhibited)

• taletrectinib
Tavneos (avacopan)

+

taletrectinib

1 interaction

Avoid/Use Alternative

avacopan + taletrectinib

avoid combo: combo may incr. taletrectinib levels, risk of QT prolongation, cardiac arrhythmias, other adverse effects (hepatic metabolism inhibited)

• tazemetostat
Tavneos (avacopan)

+

tazemetostat

1 interaction

Avoid/Use Alternative

avacopan + tazemetostat

use alternative or monitor ECG, CBC; decr. tazemetostat dose as follows: if taking 800 mg bid, decr. tazemetostat dose to 400 mg bid; if taking 600 mg bid, decr. tazemetostat dose to 400 mg qam plus 200 mg qpm; if taking 400 mg bid, decr. tazemetostat dose to 200 mg bid: combo may incr. tazemetostat levels, risk of QT prolongation, cardiac arrhythmias, myelosuppression, other adverse effects; may decr. avacopan levels, efficacy (hepatic metabolism inhibited; hepatic metabolism induced)

Monitor/Modify Tx

• abemaciclib
Tavneos (avacopan)

+

abemaciclib

1 interaction

Monitor/Modify Tx

avacopan + abemaciclib

consider decr. abemaciclib 200 mg bid dose to 150 mg bid, abemaciclib 150 mg bid dose to 100 mg bid, abemaciclib 100 mg bid dose to 50 mg bid; monitor CBC: combo may incr. abemaciclib levels, risk of myelosuppression, other adverse effects (hepatic metabolism inhibited)

• acalabrutinib
Tavneos (avacopan)

+

acalabrutinib

1 interaction

Monitor/Modify Tx

avacopan + acalabrutinib

decr. acalabrutinib dose to 100 mg qd; monitor CBC: combo may incr. acalabrutinib levels, risk of serious infection, myelosuppression, other adverse effects (hepatic metabolism inhibited, additive effects)

• adagrasib
Tavneos (avacopan)

+

adagrasib

1 interaction

Monitor/Modify Tx

avacopan + adagrasib

decr. avacopan dose to 30 mg qd; monitor ECG, electrolytes until adagrasib at steady state (approx. 8 days): combo may incr. levels of both drugs, risk of QT prolongation, cardiac arrhythmias, other adverse effects (hepatic metabolism inhibited)

• alfuzosin
Tavneos (avacopan)

+

alfuzosin

1 interaction

Monitor/Modify Tx

avacopan + alfuzosin

monitor BP, ECG: combo may incr. alfuzosin levels, risk of QT prolongation, cardiac arrhythmias, hypotension (including orthostasis, syncope), other adverse effects (hepatic metabolism inhibited)

• butorphanol
Tavneos (avacopan)

+

butorphanol

2 interactions

Monitor/Modify Tx

avacopan + butorphanol

monitor respiratory rate, consider decr. butorphanol dose: combo may incr. butorphanol levels, risk of CNS and respiratory depression, psychomotor impairment, other adverse effects (hepatic metabolism inhibited)

• capivasertib
Tavneos (avacopan)

+

capivasertib

2 interactions

Monitor/Modify Tx

avacopan + capivasertib

monitor glucose; decr. capivasertib dose to 320 mg bid x4 days followed by 3 days off: combo may incr. capivasertib levels, risk of severe hyperglycemia, other adverse effects (hepatic metabolism inhibited)

• carfilzomib
Tavneos (avacopan)

+

carfilzomib

1 interaction

Monitor/Modify Tx

avacopan + carfilzomib

consider antiviral prophylaxis: combo may incr. risk of serious infection (additive effects)

• chloramphenicol
Tavneos (avacopan)

+

chloramphenicol

1 interaction

Monitor/Modify Tx

avacopan + chloramphenicol

decr. avacopan dose to 30 mg qd: combo may incr. avacopan levels, risk of adverse effects (hepatic metabolism inhibited)

• clarithromycin
Tavneos (avacopan)

+

clarithromycin

1 interaction

Monitor/Modify Tx

avacopan + clarithromycin

decr. avacopan dose to 30 mg qd: combo may incr. avacopan levels, risk of adverse effects (hepatic metabolism inhibited)

• clozapine
Tavneos (avacopan)

+

clozapine

1 interaction

Monitor/Modify Tx

avacopan + clozapine

monitor ECG, BP, HR; consider decr. clozapine dose: combo may incr. clozapine levels, risk of QT prolongation, cardiac arrhythmias, hypotension, bradycardia, other adverse effects (hepatic metabolism inhibited)

• copanlisib
Tavneos (avacopan)

+

copanlisib

1 interaction

Monitor/Modify Tx

avacopan + copanlisib

monitor CBC: combo may incr. copanlisib levels, risk of serious infection, myelosuppression, other adverse effects (hepatic metabolism inhibited, additive effects)

• cyclosporine
Tavneos (avacopan)

+

cyclosporine

1 interaction

Monitor/Modify Tx

avacopan + cyclosporine

monitor cyclosporine levels, renal fxn: combo may incr. levels of both drugs, risk of serious infection, nephrotoxicity, other adverse effects (hepatic metabolism inhibited, additive effects)

• dasatinib
Tavneos (avacopan)

+

dasatinib

1 interaction

Monitor/Modify Tx

avacopan + dasatinib

monitor ECG, CBC: combo may incr. dasatinib levels, risk of QT prolongation, cardiac arrhythmias, myelosuppression, other adverse effects (hepatic metabolism inhibited)

• docetaxel
Tavneos (avacopan)

+

docetaxel

2 interactions

Monitor/Modify Tx

avacopan + docetaxel

monitor CBC; consider decr. docetaxel dose: combo may incr. docetaxel levels, risk of serious infection, myelosuppression, other adverse effects (hepatic metabolism inhibited, additive effects)

• dofetilide
Tavneos (avacopan)

+

dofetilide

1 interaction

Monitor/Modify Tx

avacopan + dofetilide

monitor ECG: combo may incr. dofetilide levels, risk of QT prolongation, cardiac arrhythmias, other adverse effects (hepatic metabolism inhibited)

• dronedarone
Tavneos (avacopan)

+

dronedarone

2 interactions

Monitor/Modify Tx

avacopan + dronedarone

monitor ECG: combo may incr. levels of both drugs, risk of QT prolongation, cardiac arrhythmias, other adverse effects (hepatic metabolism inhibited)

• elexacaftor/tezacaftor/ivacaftor
Tavneos (avacopan)

+

elexacaftor/ tezacaftor/ ivacaftor

1 interaction

Monitor/Modify Tx

avacopan + elexacaftor/ tezacaftor/ ivacaftor

2-5 YO: decr. usual morning dose by alternating between one elexacaftor/tezacaftor/ivacaftor packet (Day 1) and one ivacaftor packet (Day 2), no evening doses; 6 YO AND OLDER: decr. usual morning dose by alternating between two elexacaftor/tezacaftor/ivacaftor tablets (Day 1) and one ivacaftor tablet (Day 2), no evening doses: combo may incr. elexacaftor/tezacaftor/ivacaftor levels, risk of adverse effects (hepatic metabolism inhibited)

• ensitrelvir
Tavneos (avacopan)

+

ensitrelvir

1 interaction

Monitor/Modify Tx

avacopan + ensitrelvir

decr. avacopan dose to 30 mg qd: combo may incr. avacopan levels, risk of adverse effects (hepatic metabolism inhibited)

• erdafitinib
Tavneos (avacopan)

+

erdafitinib

1 interaction

Monitor/Modify Tx

avacopan + erdafitinib

monitor phosphate: combo may incr. erdafitinib levels, risk of hyperphosphatemia, other adverse effects (hepatic metabolism inhibited)

• erythromycin
Tavneos (avacopan)

+

erythromycin

1 interaction

Monitor/Modify Tx

avacopan + erythromycin

monitor ECG: combo may incr. levels of both drugs, risk of QT prolongation, cardiac arrhythmias, other adverse effects (hepatic metabolism inhibited)

• estazolam
Tavneos (avacopan)

+

estazolam

2 interactions

Monitor/Modify Tx

avacopan + estazolam

monitor respiratory rate; consider decr. estazolam dose: combo may incr. estazolam levels, risk of CNS and respiratory depression, psychomotor impairment, other adverse effects (hepatic metabolism inhibited)

• estradiol (contraceptive)
Tavneos (avacopan)

+

estradiol (contraceptive)

1 interaction

Monitor/Modify Tx

avacopan + estradiol (contraceptive)

monitor thrombosis s/sx: combo may incr. estradiol levels, risk of thromboembolism, other adverse effects (hepatic metabolism inhibited)

• everolimus
Tavneos (avacopan)

+

everolimus

1 interaction

Monitor/Modify Tx

avacopan + everolimus

BREAST CA, PNET, RENAL CELL CA, or RENAL ANGIOMYOLIPOMA WITH TSC: if also combined with P-gp inhibitor, decr. everolimus to 2.5 mg/day, may incr. to 5 mg/day if tolerated, monitor CBC; otherwise, monitor CBC; TSC-ASSOCIATED SEGA or TSC-ASSOCIATED PARTIAL-ONSET SEIZURES: if also combined with P-gp inhibitor, monitor everolimus levels, CBC and decr. everolimus 50%; give every other day if already on lowest available dose; otherwise, monitor everolimus levels, CBC; TRANSPLANT: monitor everolimus levels, CBC: combo may incr. everolimus levels, risk of serious infection, myelosuppression, other adverse effects (hepatic metabolism inhibited, additive effects)

• felodipine
Tavneos (avacopan)

+

felodipine

1 interaction

Monitor/Modify Tx

avacopan + felodipine

monitor BP, HR: combo may incr. felodipine levels, risk of hypotension, reflex tachycardia, other adverse effects (hepatic metabolism inhibited)

• futibatinib
Tavneos (avacopan)

+

futibatinib

1 interaction

Monitor/Modify Tx

avacopan + futibatinib

monitor phosphate: combo may incr. futibatinib levels, risk of hyperphosphatemia, other adverse effects (hepatic metabolism inhibited)

• gilteritinib
Tavneos (avacopan)

+

gilteritinib

1 interaction

Monitor/Modify Tx

avacopan + gilteritinib

monitor ECG: combo may incr. gilteritinib levels, risk of QT prolongation, cardiac arrhythmias, other adverse effects (hepatic metabolism inhibited)

• guanfacine
Tavneos (avacopan)

+

guanfacine

1 interaction

Monitor/Modify Tx

avacopan + guanfacine

decr. guanfacine ER dose 50%, consider decr. dose for immed.-release form: combo may incr. guanfacine levels, risk of adverse effects (hepatic metabolism inhibited)

• hydrocortisone
Tavneos (avacopan)

+

hydrocortisone

1 interaction

Monitor/Modify Tx

avacopan + hydrocortisone

consider decr. hydrocortisone dose: combo may incr. hydrocortisone levels, risk of serious infection, systemic corticosteroid effects, including Cushing syndrome and adrenal suppression, other adverse effects (hepatic metabolism inhibited, additive effects)

• ibrutinib
Tavneos (avacopan)

+

ibrutinib

2 interactions

Monitor/Modify Tx

avacopan + ibrutinib

B-CELL MALIGNANCIES: decr. ibrutinib dose to 280 mg qd; CHRONIC GVHD: consider decr. ibrutinib dose: combo may incr. ibrutinib levels, risk of serious infection, myelosuppression, other adverse effects (hepatic metabolism inhibited, additive effects)

• idelalisib
Tavneos (avacopan)

+

idelalisib

1 interaction

Monitor/Modify Tx

avacopan + idelalisib

decr. avacopan dose to 30 mg qd: combo may incr. avacopan levels, risk of serious infection, other adverse effects (hepatic metabolism inhibited, additive effects)

• iloperidone
Tavneos (avacopan)

+

iloperidone

2 interactions

Monitor/Modify Tx

avacopan + iloperidone

monitor ECG: combo may incr. iloperidone levels, risk of QT prolongation, cardiac arrhythmias, other adverse effects (hepatic metabolism inhibited)

• irinotecan
Tavneos (avacopan)

+

irinotecan

1 interaction

Monitor/Modify Tx

avacopan + irinotecan

monitor CBC: combo may incr. irinotecan and active metabolite levels, risk of serious infection, myelosuppression, other toxicities (hepatic metabolism inhibited, additive effects)

• itraconazole
Tavneos (avacopan)

+

itraconazole

2 interactions

Monitor/Modify Tx

avacopan + itraconazole

decr. avacopan dose to 30 mg qd; consider decr. itraconazole dose: combo may incr. levels of both drugs, risk of adverse effects (hepatic metabolism inhibited)

• ketoconazole
Tavneos (avacopan)

+

ketoconazole

1 interaction

Monitor/Modify Tx

avacopan + ketoconazole

decr. avacopan dose to 30 mg qd: combo may incr. avacopan levels, risk of adverse effects (hepatic metabolism inhibited)

• lapatinib
Tavneos (avacopan)

+

lapatinib

2 interactions

Monitor/Modify Tx

avacopan + lapatinib

monitor ECG; consider decr. lapatinib dose: combo may incr. lapatinib levels, risk of QT prolongation, cardiac arrhythmias, other adverse effects (hepatic metabolism inhibited)

• larotrectinib
Tavneos (avacopan)

+

larotrectinib

1 interaction

Monitor/Modify Tx

avacopan + larotrectinib

caution advised: combo may incr. larotrectinib levels, risk of adverse effects (hepatic metabolism inhibited)

• lefamulin
Tavneos (avacopan)

+

lefamulin

2 interactions

Monitor/Modify Tx

avacopan + lefamulin

ORAL LEFAMULIN: monitor ECG; IV lefamulin use OK: combo may incr. levels of both drugs, risk of QT prolongation, cardiac arrhythmias, other adverse effects (hepatic metabolism inhibited)

• lidocaine
Tavneos (avacopan)

+

lidocaine

1 interaction

Monitor/Modify Tx

avacopan + lidocaine

monitor lidocaine levels if lidocaine antiarrhythmic use; otherwise, monitor BP, HR: combo may incr. lidocaine levels, risk of hypotension, bradycardia, other adverse effects; risk may be higher with continuous infusion or higher doses for local anesthesia (hepatic metabolism inhibited)

• lumateperone
Tavneos (avacopan)

+

lumateperone

2 interactions

Monitor/Modify Tx

avacopan + lumateperone

monitor ECG; decr. lumateperone dose to 21 mg qd: combo may incr. lumateperone levels, risk of QT prolongation, cardiac arrhythmias, other adverse effects (hepatic metabolism inhibited)

• lurasidone
Tavneos (avacopan)

+

lurasidone

1 interaction

Monitor/Modify Tx

avacopan + lurasidone

monitor ECG; decr. lurasidone start dose to 20 mg or decr. usual lurasidone dose 50%, max 80 mg/day: combo may incr. lurasidone levels, risk of QT prolongation, cardiac arrhythmias, other adverse effects (hepatic metabolism inhibited)

• mavorixafor
Tavneos (avacopan)

+

mavorixafor

2 interactions

Monitor/Modify Tx

avacopan + mavorixafor

monitor ECG: combo may incr. mavorixafor levels, risk of QT prolongation, cardiac arrhythmias, other adverse effects (hepatic metabolism inhibited)

• mefloquine
Tavneos (avacopan)

+

mefloquine

1 interaction

Monitor/Modify Tx

avacopan + mefloquine

monitor ECG: combo may incr. mefloquine levels, risk of QT prolongation, cardiac arrhythmias, other adverse effects (hepatic metabolism inhibited)

• mifepristone
Tavneos (avacopan)

+

mifepristone

1 interaction

Monitor/Modify Tx

avacopan + mifepristone

monitor ECG; decr. avacopan dose to 30 mg qd during and x14 days after daily mifepristone use; caution advised if pregnancy termination use: combo may incr. levels of both drugs, risk of QT prolongation, cardiac arrhythmias, other adverse effects (hepatic metabolism inhibited)

• mitomycin
Tavneos (avacopan)

+

mitomycin

1 interaction

Monitor/Modify Tx

avacopan + mitomycin

caution advised; risk may be lower w/ intravesical mitomycin administration: combo may incr. risk of serious infection (additive effects)

• nelfinavir
Tavneos (avacopan)

+

nelfinavir

1 interaction

Monitor/Modify Tx

avacopan + nelfinavir

decr. avacopan dose to 30 mg qd: combo may incr. avacopan levels, risk of adverse effects (hepatic metabolism inhibited)

• nilotinib
Tavneos (avacopan)

+

nilotinib

1 interaction

Monitor/Modify Tx

avacopan + nilotinib

monitor ECG, CBC: combo may incr. levels of both drugs, risk of QT prolongation, cardiac arrhythmias, myelosuppression, other adverse effects (hepatic metabolism inhibited)

• nortriptyline
Tavneos (avacopan)

+

nortriptyline

1 interaction

Monitor/Modify Tx

avacopan + nortriptyline

consider monitoring nortriptyline levels: combo may incr. nortriptyline levels, risk of adverse effects (hepatic metabolism inhibited)

• oveporexton
Tavneos (avacopan)

+

oveporexton

1 interaction

Monitor/Modify Tx

avacopan + oveporexton

decr. oveporexton dose to 0.5 mg after awakening and 0.5 mg 3-5h later: combo may incr. oveporexton levels, risk of adverse effects (hepatic metabolism inhibited)

• palbociclib
Tavneos (avacopan)

+

palbociclib

2 interactions

Monitor/Modify Tx

avacopan + palbociclib

monitor CBC: combo may incr. palbociclib levels, risk of myelosuppression, other adverse effects (hepatic metabolism inhibited)

• pazopanib
Tavneos (avacopan)

+

pazopanib

1 interaction

Monitor/Modify Tx

avacopan + pazopanib

monitor ECG: combo may incr. pazopanib levels, risk of QT prolongation, cardiac arrhythmias, other adverse effects (hepatic metabolism inhibited)

• pirtobrutinib
Tavneos (avacopan)

+

pirtobrutinib

1 interaction

Monitor/Modify Tx

avacopan + pirtobrutinib

monitor CBC: combo may incr. pirtobrutinib levels, risk of serious infection, myelosuppression, other adverse effects (hepatic metabolism inhibited, additive effects)

• posaconazole
Tavneos (avacopan)

+

posaconazole

1 interaction

Monitor/Modify Tx

avacopan + posaconazole

decr. avacopan dose to 30 mg qd: combo may incr. avacopan levels, risk of adverse effects (hepatic metabolism inhibited)

• quetiapine
Tavneos (avacopan)

+

quetiapine

1 interaction

Monitor/Modify Tx

avacopan + quetiapine

monitor ECG; consider decr. quetiapine dose: combo may incr. quetiapine levels, risk of QT prolongation, cardiac arrhythmias, other adverse effects (hepatic metabolism inhibited)

• quinidine (antiarrhythmic)
Tavneos (avacopan)

+

quinidine (antiarrhythmic)

2 interactions

Monitor/Modify Tx

avacopan + quinidine (antiarrhythmic)

monitor quinidine levels, ECG: combo may incr. quinidine levels, risk of QT prolongation, cardiac arrhythmias, other adverse effects (hepatic metabolism inhibited)

• quinidine (CYP2D6 inhibitor)
Tavneos (avacopan)

+

quinidine (CYP2D6 inhibitor)

1 interaction

Monitor/Modify Tx

avacopan + quinidine (CYP2D6 inhibitor)

monitor ECG: combo may incr. quinidine levels, risk of QT prolongation, cardiac arrhythmias, other adverse effects (hepatic metabolism inhibited)

• quinine
Tavneos (avacopan)

+

quinine

2 interactions

Monitor/Modify Tx

avacopan + quinine

monitor ECG: combo may incr. quinine levels, risk of QT prolongation, cardiac arrhythmias, other adverse effects (hepatic metabolism inhibited)

• ranolazine
Tavneos (avacopan)

+

ranolazine

1 interaction

Monitor/Modify Tx

avacopan + ranolazine

adjust ranolazine max dose to 1000 mg/day: combo may incr. ranolazine levels, risk of QT prolongation, cardiac arrhythmias, other adverse effects (hepatic metabolism inhibited)

• red yeast rice
Tavneos (avacopan)

+

red yeast rice

2 interactions

Monitor/Modify Tx

avacopan + red yeast rice

monitor CK, myopathy sx w/ large amounts of red yeast rice: combo may incr. lovastatin levels, risk of myopathy, rhabdomyolysis, other adverse effects (hepatic metabolism inhibited, red yeast rice contains varying amounts of lovastatin)

• relacorilant
Tavneos (avacopan)

+

relacorilant

1 interaction

Monitor/Modify Tx

avacopan + relacorilant

decr. avacopan dose to 30 mg qd: combo may incr. avacopan levels, risk of serious infection, other adverse effects (hepatic metabolism inhibited, additive effects)

• ribociclib
Tavneos (avacopan)

+

ribociclib

1 interaction

Monitor/Modify Tx

avacopan + ribociclib

monitor ECG, electrolytes, CBC; decr. avacopan dose to 30 mg qd: combo may incr. levels of both drugs, risk of QT prolongation, cardiac arrhythmias, myelosuppression, other adverse effects (hepatic metabolism inhibited)

• riociguat
Tavneos (avacopan)

+

riociguat

1 interaction

Monitor/Modify Tx

avacopan + riociguat

monitor BP: combo may incr. riociguat levels, risk of severe hypotension, other adverse effects (hepatic metabolism inhibited)

• ruxolitinib
Tavneos (avacopan)

+

ruxolitinib

1 interaction

Monitor/Modify Tx

avacopan + ruxolitinib

monitor CBC: combo may incr. ruxolitinib levels, risk of serious infection, myelosuppression, other adverse effects (hepatic metabolism inhibited, additive effects)

• saxagliptin
Tavneos (avacopan)

+

saxagliptin

1 interaction

Monitor/Modify Tx

avacopan + saxagliptin

monitor glucose: combo may incr. saxagliptin levels, risk of hypoglycemia, other adverse effects (hepatic metabolism inhibited)

• sertraline
Tavneos (avacopan)

+

sertraline

1 interaction

Monitor/Modify Tx

avacopan + sertraline

monitor ECG: combo may incr. sertraline levels, risk of QT prolongation, cardiac arrhythmias, other adverse effects (hepatic metabolism inhibited)

• sipuleucel-T
Tavneos (avacopan)

+

sipuleucel-T

1 interaction

Monitor/Modify Tx

avacopan + sipuleucel-T

consider decr. avacopan dose or D/C during leukapheresis and sipuleucel-T admin.: combo may decr. efficacy of sipuleucel-T; may incr. risk of adverse effects (antagonistic effects; additive effects)

• sirolimus albumin-bound
Tavneos (avacopan)

+

sirolimus albumin-bound

1 interaction

Monitor/Modify Tx

avacopan + sirolimus albumin-bound

decr. sirolimus albumin-bound dose to 56 mg/m2; monitor CBC, bleeding s/sx: combo may incr. sirolimus albumin-bound levels, risk of serious infection, myelosuppression, bleeding (including life-threatening), other adverse effects (hepatic metabolism inhibited, additive effects)

• sparsentan
Tavneos (avacopan)

+

sparsentan

1 interaction

Monitor/Modify Tx

avacopan + sparsentan

monitor BP, potassium, renal fxn: combo may incr. sparsentan levels, risk of hypotension (including orthostasis, syncope), hyperkalemia, edema, nephrotoxicity, other adverse effects (hepatic metabolism inhibited)

• sunitinib
Tavneos (avacopan)

+

sunitinib

2 interactions

Monitor/Modify Tx

avacopan + sunitinib

consider monitoring ECG, electrolytes: combo may incr. sunitinib levels, risk of QT prolongation, cardiac arrhythmias, other adverse effects (hepatic metabolism inhibited)

• suvorexant
Tavneos (avacopan)

+

suvorexant

1 interaction

Monitor/Modify Tx

avacopan + suvorexant

decr. suvorexant dose to 5 mg, max 10 mg/day: combo may incr. suvorexant levels, risk of CNS depression, psychomotor impairment, other adverse effects (hepatic metabolism inhibited)

• suzetrigine
Tavneos (avacopan)

+

suzetrigine

1 interaction

Monitor/Modify Tx

avacopan + suzetrigine

start suzetrigine 100 mg x1 at least 1h before or 2h after food, after 12h give 50 mg q12h x3 doses, then after 12h give 50mg q24h: combo may incr. suzetrigine and active metabolite levels, risk of adverse effects; may decr. avacopan levels, efficacy (hepatic metabolism inhibited; hepatic metabolism induced)

• tacrolimus
Tavneos (avacopan)

+

tacrolimus

1 interaction

Monitor/Modify Tx

avacopan + tacrolimus

monitor tacrolimus levels, ECG, renal fxn: combo may incr. tacrolimus levels, risk of QT prolongation, cardiac arrhythmias, nephrotoxicity, serious infection, other adverse effects (hepatic metabolism inhibited, additive effects)

• tadalafil
Tavneos (avacopan)

+

tadalafil

2 interactions

Monitor/Modify Tx

avacopan + tadalafil

monitor BP: combo may incr. tadalafil levels, risk of hypotension, priapism, other adverse effects (hepatic metabolism inhibited)

• tamsulosin
Tavneos (avacopan)

+

tamsulosin

1 interaction

Monitor/Modify Tx

avacopan + tamsulosin

monitor BP, especially w/ tamsulosin dose >0.4 mg: combo may incr. tamsulosin levels, risk of hypotension (including orthostasis, syncope), other adverse effects (hepatic metabolism inhibited)

• tezacaftor/ivacaftor
Tavneos (avacopan)

+

tezacaftor/ ivacaftor

1 interaction

Monitor/Modify Tx

avacopan + tezacaftor/ ivacaftor

decr. dose by alternating tezacaftor/ivacaftor tab and ivacaftor tab at morning dose, no evening doses: combo may incr. tezacaftor/ivacaftor levels, risk of adverse effects (hepatic metabolism inhibited)

• tofacitinib
Tavneos (avacopan)

+

tofacitinib

1 interaction

Monitor/Modify Tx

avacopan + tofacitinib

ALL USES: monitor CBC; if also combined w/ strong CYP2C19 inhibitor, adjust tofacitinib as follows: ADULT RHEUMATOID or PSORIATIC ARTHRITIS or ANKYLOSING SPONDYLITIS: decr. to 5 mg qd; ADULT ULCERATIVE COLITIS: decr. induction to 5 mg bid using tabs or 11 mg qd using XR tab for up to 16 wks, followed by 5 mg qd maintenance using tabs; do not use XR tabs for maintenance doses; PEDIATRIC PSORIATIC ARTHRITIS, POLYARTICULAR COURSE JUVENILE IDIOPATHIC ARTHRITIS: decr. usual bid dose to qd: combo may incr. tofacitinib levels, risk of serious infection, myelosuppression, other adverse effects (hepatic metabolism inhibited, additive effects)

• trabectedin
Tavneos (avacopan)

+

trabectedin

2 interactions

Monitor/Modify Tx

avacopan + trabectedin

monitor CBC, cardiac function (including LVEF), LFTs: combo may incr. trabectedin levels, risk of myelosuppression, cardiotoxicity, hepatotoxicity, other adverse effects (hepatic metabolism inhibited, additive effects)

• trazodone
Tavneos (avacopan)

+

trazodone

1 interaction

Monitor/Modify Tx

avacopan + trazodone

monitor ECG, BP: combo may incr. trazodone levels, risk of QT prolongation, cardiac arrhythmias, hypotension (including orthostasis, syncope), other adverse effects (hepatic metabolism inhibited)

• tucatinib
Tavneos (avacopan)

+

tucatinib

1 interaction

Monitor/Modify Tx

avacopan + tucatinib

decr. avacopan dose to 30 mg qd: combo may incr. avacopan levels, risk of adverse effects (hepatic metabolism inhibited)

• vanzacaftor/tezacaftor/deutivacaftor
Tavneos (avacopan)

+

vanzacaftor/ tezacaftor/ deutivacaftor

1 interaction

Monitor/Modify Tx

avacopan + vanzacaftor/ tezacaftor/ deutivacaftor

6-11 YO AND WT <40 KG: decr. vanzacaftor/tezacaftor/deutivacaftor dose to two tablets (4 mg/20 mg/50 mg each) qod; 6-11 YO AND WT 40 KG AND ABOVE: decr. vanzacaftor/tezacaftor/deutivacaftor dose to one tablet (10 mg/50 mg/125 mg) qod; 12 YO AND OLDER: decr. vanzacaftor/tezacaftor/deutivacaftor dose to one tablet (10 mg/50 mg/125 mg) qod: combo may incr. vanzacaftor/tezacaftor/deutivacaftor levels, risk of adverse effects (hepatic metabolism inhibited)

• vemurafenib
Tavneos (avacopan)

+

vemurafenib

1 interaction

Monitor/Modify Tx

avacopan + vemurafenib

monitor ECG: combo may incr. vemurafenib levels, risk of QT prolongation, cardiac arrhythmias, other adverse effects; may decr. avacopan levels, efficacy (hepatic metabolism inhibited; hepatic metabolism induced)

• vepdegestrant
Tavneos (avacopan)

+

vepdegestrant

2 interactions

Monitor/Modify Tx

avacopan + vepdegestrant

monitor ECG: combo may incr. vepdegestrant levels, risk of QT prolongation, cardiac arrhythmias, other adverse effects (hepatic metabolism inhibited)

• vinblastine
Tavneos (avacopan)

+

vinblastine

1 interaction

Monitor/Modify Tx

avacopan + vinblastine

monitor CBC: combo may incr. vinblastine levels, risk of serious infection, myelosuppression, autonomic neuropathy, other adverse effects; may decr. avacopan levels, efficacy (hepatic metabolism inhibited, additive effects; hepatic metabolism induced)

• vinorelbine
Tavneos (avacopan)

+

vinorelbine

1 interaction

Monitor/Modify Tx

avacopan + vinorelbine

monitor CBC: combo may incr. vinorelbine levels, risk of serious infection, myelosuppression, autonomic neuropathy, other adverse effects (hepatic metabolism inhibited, additive effects)

• voriconazole
Tavneos (avacopan)

+

voriconazole

1 interaction

Monitor/Modify Tx

avacopan + voriconazole

decr. avacopan dose to 30 mg qd: combo may incr. avacopan levels, risk of adverse effects (hepatic metabolism inhibited)

• zanubrutinib
Tavneos (avacopan)

+

zanubrutinib

1 interaction

Monitor/Modify Tx

avacopan + zanubrutinib

decr. zanubrutinib dose to 80 mg bid; monitor CBC: combo may incr. zanubrutinib levels, risk of serious infection, myelosuppression, other adverse effects; may decr. avacopan levels, efficacy (hepatic metabolism inhibited, additive effects; hepatic metabolism induced)

Caution Advised

• abatacept
Tavneos (avacopan)

+

abatacept

1 interaction

Caution Advised

avacopan + abatacept

caution advised: combo may incr. risk of serious infection (additive effects)

• abrocitinib
Tavneos (avacopan)

+

abrocitinib

1 interaction

Caution Advised

avacopan + abrocitinib

caution advised: combo may incr. risk of serious infection (additive effects)

• adalimumab
Tavneos (avacopan)

+

adalimumab

1 interaction

Caution Advised

avacopan + adalimumab

caution advised: combo may incr. risk of serious infection (additive effects)

• afamitresgene autoleucel
Tavneos (avacopan)

+

afamitresgene autoleucel

2 interactions

Caution Advised

avacopan + afamitresgene autoleucel

caution advised: combo may incr. risk of serious infection (additive effects)

• aldesleukin
Tavneos (avacopan)

+

aldesleukin

1 interaction

Caution Advised

avacopan + aldesleukin

caution advised: combo may incr. risk of serious infection (additive effects)

• alemtuzumab
Tavneos (avacopan)

+

alemtuzumab

2 interactions

Caution Advised

avacopan + alemtuzumab

caution advised: combo may incr. risk of serious infection (additive effects)

• aliskiren
Tavneos (avacopan)

+

aliskiren

1 interaction

Caution Advised

avacopan + aliskiren

caution advised: combo may incr. aliskiren levels, risk of adverse effects (hepatic metabolism inhibited)

• anakinra
Tavneos (avacopan)

+

anakinra

1 interaction

Caution Advised

avacopan + anakinra

caution advised: combo may incr. risk of serious infection (additive effects)

• anifrolumab
Tavneos (avacopan)

+

anifrolumab

1 interaction

Caution Advised

avacopan + anifrolumab

caution advised: combo may incr. risk of serious infection (additive effects)

• anti-thymocyte globulin
Tavneos (avacopan)

+

anti-thymocyte globulin

1 interaction

Caution Advised

avacopan + anti-thymocyte globulin

caution advised: combo may incr. risk of serious infection (additive effects)

• armodafinil
Tavneos (avacopan)

+

armodafinil

1 interaction

Caution Advised

avacopan + armodafinil

caution advised: combo may decr. avacopan levels, efficacy (hepatic metabolism induced)

• atacicept
Tavneos (avacopan)

+

atacicept

1 interaction

Caution Advised

avacopan + atacicept

caution advised: combo may incr. risk of serious infection (additive effects)

• atidarsagene autotemcel
Tavneos (avacopan)

+

atidarsagene autotemcel

2 interactions

Caution Advised

avacopan + atidarsagene autotemcel

caution advised: combo may incr. risk of serious infection (additive effects)

• axicabtagene ciloleucel
Tavneos (avacopan)

+

axicabtagene ciloleucel

1 interaction

Caution Advised

avacopan + axicabtagene ciloleucel

caution advised: combo may incr. risk of serious infection (additive effects)

• azacitidine
Tavneos (avacopan)

+

azacitidine

2 interactions

Caution Advised

avacopan + azacitidine

caution advised: combo may incr. risk of serious infection (additive effects)

• azathioprine
Tavneos (avacopan)

+

azathioprine

1 interaction

Caution Advised

avacopan + azathioprine

caution advised: combo may incr. risk of serious infection (additive effects)

• baricitinib
Tavneos (avacopan)

+

baricitinib

1 interaction

Caution Advised

avacopan + baricitinib

caution advised: combo may incr. risk of serious infection (additive effects)

• basiliximab
Tavneos (avacopan)

+

basiliximab

1 interaction

Caution Advised

avacopan + basiliximab

caution advised: combo may incr. risk of serious infection (additive effects)

• beclomethasone inhaled
Tavneos (avacopan)

+

beclomethasone inhaled

1 interaction

Caution Advised

avacopan + beclomethasone inhaled

caution advised: combo may incr. risk of serious infection (additive effects)

• beclomethasone nasal
Tavneos (avacopan)

+

beclomethasone nasal

1 interaction

Caution Advised

avacopan + beclomethasone nasal

caution advised: combo may incr. risk of serious infection (additive effects)

• belimumab
Tavneos (avacopan)

+

belimumab

1 interaction

Caution Advised

avacopan + belimumab

caution advised: combo may incr. risk of serious infection (additive effects)

• belinostat
Tavneos (avacopan)

+

belinostat

1 interaction

Caution Advised

avacopan + belinostat

caution advised: combo may incr. risk of serious infection (additive effects)

• belzutifan
Tavneos (avacopan)

+

belzutifan

1 interaction

Caution Advised

avacopan + belzutifan

caution advised: combo may decr. avacopan levels, efficacy (hepatic metabolism induced)

• bendamustine
Tavneos (avacopan)

+

bendamustine

1 interaction

Caution Advised

avacopan + bendamustine

caution advised: combo may incr. risk of serious infection (additive effects)

• berotralstat
Tavneos (avacopan)

+

berotralstat

1 interaction

Caution Advised

avacopan + berotralstat

caution advised: combo may incr. avacopan levels, risk of adverse effects (hepatic metabolism inhibited)

• betamethasone
Tavneos (avacopan)

+

betamethasone

1 interaction

Caution Advised

avacopan + betamethasone

caution advised: combo may incr. risk of serious infection (additive effects)

• bexarotene
Tavneos (avacopan)

+

bexarotene

1 interaction

Caution Advised

avacopan + bexarotene

caution advised: combo may decr. avacopan levels, efficacy (hepatic metabolism induced)

• bimekizumab
Tavneos (avacopan)

+

bimekizumab

1 interaction

Caution Advised

avacopan + bimekizumab

caution advised: combo may incr. risk of serious infection (additive effects)

• blinatumomab
Tavneos (avacopan)

+

blinatumomab

1 interaction

Caution Advised

avacopan + blinatumomab

caution advised: combo may incr. risk of serious infection (additive effects)

• bortezomib
Tavneos (avacopan)

+

bortezomib

1 interaction

Caution Advised

avacopan + bortezomib

caution advised: combo may incr. risk of serious infection (additive effects)

• brentuximab vedotin
Tavneos (avacopan)

+

brentuximab vedotin

2 interactions

Caution Advised

avacopan + brentuximab vedotin

caution advised: combo may incr. risk of serious infection (additive effects)

• brexucabtagene autoleucel
Tavneos (avacopan)

+

brexucabtagene autoleucel

1 interaction

Caution Advised

avacopan + brexucabtagene autoleucel

caution advised: combo may incr. risk of serious infection (additive effects)

• brodalumab
Tavneos (avacopan)

+

brodalumab

2 interactions

Caution Advised

avacopan + brodalumab

caution advised: combo may incr. risk of serious infection (additive effects)

• budesonide inhaled
Tavneos (avacopan)

+

budesonide inhaled

1 interaction

Caution Advised

avacopan + budesonide inhaled

caution advised: combo may incr. risk of serious infection (additive effects)

• budesonide nasal
Tavneos (avacopan)

+

budesonide nasal

2 interactions

Caution Advised

avacopan + budesonide nasal

caution advised: combo may incr. risk of serious infection (additive effects)

• budesonide rectal
Tavneos (avacopan)

+

budesonide rectal

1 interaction

Caution Advised

avacopan + budesonide rectal

caution advised: combo may incr. budesonide levels, risk of systemic corticosteroid effects including Cushing syndrome and adrenal suppression, serious infection, other adverse effects (hepatic metabolism inhibited, additive effects)

• busulfan
Tavneos (avacopan)

+

busulfan

2 interactions

Caution Advised

avacopan + busulfan

caution advised: combo may incr. risk of serious infection (additive effects)

• cabazitaxel
Tavneos (avacopan)

+

cabazitaxel

1 interaction

Caution Advised

avacopan + cabazitaxel

caution advised: combo may incr. risk of serious infection (additive effects)

• canakinumab
Tavneos (avacopan)

+

canakinumab

2 interactions

Caution Advised

avacopan + canakinumab

caution advised: combo may incr. risk of serious infection (additive effects)

• carboplatin
Tavneos (avacopan)

+

carboplatin

1 interaction

Caution Advised

avacopan + carboplatin

caution advised: combo may incr. risk of serious infection (additive effects)

• carmustine
Tavneos (avacopan)

+

carmustine

1 interaction

Caution Advised

avacopan + carmustine

caution advised: combo may incr. risk of serious infection (additive effects)

• certolizumab pegol
Tavneos (avacopan)

+

certolizumab pegol

1 interaction

Caution Advised

avacopan + certolizumab pegol

caution advised: combo may incr. risk of serious infection (additive effects)

• chlorambucil
Tavneos (avacopan)

+

chlorambucil

1 interaction

Caution Advised

avacopan + chlorambucil

caution advised: combo may incr. risk of serious infection (additive effects)

• ciclesonide
Tavneos (avacopan)

+

ciclesonide

1 interaction

Caution Advised

avacopan + ciclesonide

caution advised: combo may incr. risk of serious infection (additive effects)

• ciltacabtagene autoleucel
Tavneos (avacopan)

+

ciltacabtagene autoleucel

1 interaction

Caution Advised

avacopan + ciltacabtagene autoleucel

caution advised: combo may incr. risk of serious infection (additive effects)

• ciprofloxacin
Tavneos (avacopan)

+

ciprofloxacin

1 interaction

Caution Advised

avacopan + ciprofloxacin

caution advised: combo may incr. avacopan levels, risk of adverse effects (hepatic metabolism inhibited)

• cisplatin
Tavneos (avacopan)

+

cisplatin

1 interaction

Caution Advised

avacopan + cisplatin

caution advised: combo may incr. risk of serious infection (additive effects)

• cladribine injection
Tavneos (avacopan)

+

cladribine injection

1 interaction

Caution Advised

avacopan + cladribine injection

caution advised: combo may incr. risk of serious infection (additive effects)

• clobazam
Tavneos (avacopan)

+

clobazam

1 interaction

Caution Advised

avacopan + clobazam

caution advised: combo may decr. avacopan levels, efficacy (hepatic metabolism induced)

• clobetasol ophthalmic
Tavneos (avacopan)

+

clobetasol ophthalmic

1 interaction

Caution Advised

avacopan + clobetasol ophthalmic

caution advised: combo may incr. risk of serious infection (additive effects)

• clofarabine
Tavneos (avacopan)

+

clofarabine

1 interaction

Caution Advised

avacopan + clofarabine

caution advised: combo may incr. risk of serious infection (additive effects)

• clofazimine
Tavneos (avacopan)

+

clofazimine

1 interaction

Caution Advised

avacopan + clofazimine

caution advised: combo may incr. avacopan levels, risk of adverse effects (hepatic metabolism inhibited)

• coccidioides immitis skin test antigen
Tavneos (avacopan)

+

coccidioides immitis skin test antigen

1 interaction

Caution Advised

avacopan + coccidioides immitis skin test antigen

caution advised: combo may interfere with test results (antagonistic effects)

• corticotropin
Tavneos (avacopan)

+

corticotropin

1 interaction

Caution Advised

avacopan + corticotropin

caution advised: combo may incr. risk of serious infection (additive effects)

• cortisone
Tavneos (avacopan)

+

cortisone

1 interaction

Caution Advised

avacopan + cortisone

caution advised: combo may incr. risk of serious infection (additive effects)

• crovalimab
Tavneos (avacopan)

+

crovalimab

1 interaction

Caution Advised

avacopan + crovalimab

caution advised: combo may incr. risk of serious infection (additive effects)

• cyclophosphamide
Tavneos (avacopan)

+

cyclophosphamide

1 interaction

Caution Advised

avacopan + cyclophosphamide

caution advised: combo may decr. cyclophosphamide active metabolite levels, efficacy; may incr. risk of serious infection (hepatic metabolism possibly inhibited, decr. conversion to active metabolite; additive effects)

• cytarabine
Tavneos (avacopan)

+

cytarabine

1 interaction

Caution Advised

avacopan + cytarabine

caution advised: combo may incr. risk of serious infection (additive effects)

• dactinomycin
Tavneos (avacopan)

+

dactinomycin

2 interactions

Caution Advised

avacopan + dactinomycin

caution advised: combo may incr. risk of serious infection (additive effects)

• danazol
Tavneos (avacopan)

+

danazol

1 interaction

Caution Advised

avacopan + danazol

caution advised: combo may incr. avacopan levels, risk of adverse effects (hepatic metabolism inhibited)

• danicopan
Tavneos (avacopan)

+

danicopan

2 interactions

Caution Advised

avacopan + danicopan

caution advised: combo may incr. risk of serious infection (additive effects)

• danshen
Tavneos (avacopan)

+

danshen

1 interaction

Caution Advised

avacopan + danshen

caution advised: combo may decr. avacopan levels, efficacy (hepatic metabolism induced)

• daratumumab
Tavneos (avacopan)

+

daratumumab

1 interaction

Caution Advised

avacopan + daratumumab

caution advised: combo may incr. risk of serious infection (additive effects)

• darifenacin
Tavneos (avacopan)

+

darifenacin

1 interaction

Caution Advised

avacopan + darifenacin

caution advised: combo may incr. darifenacin levels, risk of adverse effects (hepatic metabolism inhibited)

• darolutamide
Tavneos (avacopan)

+

darolutamide

1 interaction

Caution Advised

avacopan + darolutamide

caution advised: combo may decr. avacopan levels, efficacy (hepatic metabolism induced)

• darunavir
Tavneos (avacopan)

+

darunavir

1 interaction

Caution Advised

avacopan + darunavir

caution advised: combo may incr. avacopan levels, risk of adverse effects (hepatic metabolism inhibited)

• daunorubicin
Tavneos (avacopan)

+

daunorubicin

1 interaction

Caution Advised

avacopan + daunorubicin

caution advised: combo may incr. risk of serious infection (additive effects)

• decitabine
Tavneos (avacopan)

+

decitabine

1 interaction

Caution Advised

avacopan + decitabine

caution advised: combo may incr. risk of serious infection (additive effects)

• delgocitinib topical
Tavneos (avacopan)

+

delgocitinib topical

1 interaction

Caution Advised

avacopan + delgocitinib topical

caution advised: combo may incr. risk of serious infection (additive effects)

• deucravacitinib
Tavneos (avacopan)

+

deucravacitinib

1 interaction

Caution Advised

avacopan + deucravacitinib

caution advised: combo may incr. risk of serious infection (additive effects)

• deuruxolitinib
Tavneos (avacopan)

+

deuruxolitinib

1 interaction

Caution Advised

avacopan + deuruxolitinib

caution advised: combo may incr. risk of serious infection (additive effects)

• dexamethasone
Tavneos (avacopan)

+

dexamethasone

1 interaction

Caution Advised

avacopan + dexamethasone

caution advised: combo may incr. dexamethasone levels, risk of systemic corticosteroid effects including Cushing syndrome and adrenal suppression, serious infection, other adverse effects; may decr. avacopan levels, efficacy (hepatic metabolism inhibited, additive effects; hepatic metabolism induced)

• dexamethasone ophthalmic
Tavneos (avacopan)

+

dexamethasone ophthalmic

1 interaction

Caution Advised

avacopan + dexamethasone ophthalmic

caution advised: combo may incr. risk of serious infection (additive effects)

• dicloxacillin
Tavneos (avacopan)

+

dicloxacillin

1 interaction

Caution Advised

avacopan + dicloxacillin

caution advised: combo may decr. avacopan levels, efficacy (hepatic metabolism induced)

• difluprednate ophthalmic
Tavneos (avacopan)

+

difluprednate ophthalmic

1 interaction

Caution Advised

avacopan + difluprednate ophthalmic

caution advised: combo may incr. risk of serious infection (additive effects)

• diltiazem
Tavneos (avacopan)

+

diltiazem

2 interactions

Caution Advised

avacopan + diltiazem

caution advised: combo may incr. avacopan levels, risk of adverse effects (hepatic metabolism inhibited)

• dimethyl fumarate
Tavneos (avacopan)

+

dimethyl fumarate

1 interaction

Caution Advised

avacopan + dimethyl fumarate

caution advised: combo may incr. risk of serious infection (additive effects)

• dinutuximab
Tavneos (avacopan)

+

dinutuximab

2 interactions

Caution Advised

avacopan + dinutuximab

caution advised: combo may incr. risk of serious infection (additive effects)

• diroximel fumarate
Tavneos (avacopan)

+

diroximel fumarate

1 interaction

Caution Advised

avacopan + diroximel fumarate

caution advised: combo may incr. risk of serious infection (additive effects)

• dupilumab
Tavneos (avacopan)

+

dupilumab

2 interactions

Caution Advised

avacopan + dupilumab

caution advised: combo may incr. risk of serious infection (additive effects)

• duvelisib
Tavneos (avacopan)

+

duvelisib

1 interaction

Caution Advised

avacopan + duvelisib

caution advised: combo may incr. avacopan levels, risk of serious infection, other adverse effects (hepatic metabolism inhibited, additive effects)

• echinacea
Tavneos (avacopan)

+

echinacea

2 interactions

Caution Advised

avacopan + echinacea

caution advised: combo may decr. avacopan levels, efficacy (hepatic metabolism induced)

• eculizumab
Tavneos (avacopan)

+

eculizumab

1 interaction

Caution Advised

avacopan + eculizumab

caution advised: combo may incr. risk of serious infection (additive effects)

• efgartigimod alfa
Tavneos (avacopan)

+

efgartigimod alfa

1 interaction

Caution Advised

avacopan + efgartigimod alfa

caution advised: combo may incr. risk of serious infection (additive effects)

• elafibranor
Tavneos (avacopan)

+

elafibranor

1 interaction

Caution Advised

avacopan + elafibranor

caution advised: combo may decr. avacopan levels, efficacy (hepatic metabolism induced)

• eletriptan
Tavneos (avacopan)

+

eletriptan

1 interaction

Caution Advised

avacopan + eletriptan

caution advised: combo may incr. eletriptan levels, risk of adverse effects (hepatic metabolism inhibited)

• elivaldogene autotemcel
Tavneos (avacopan)

+

elivaldogene autotemcel

1 interaction

Caution Advised

avacopan + elivaldogene autotemcel

caution advised: combo may incr. risk of serious infection (additive effects)

• elotuzumab
Tavneos (avacopan)

+

elotuzumab

2 interactions

Caution Advised

avacopan + elotuzumab

caution advised: combo may incr. risk of serious infection (additive effects)

• elranatamab
Tavneos (avacopan)

+

elranatamab

1 interaction

Caution Advised

avacopan + elranatamab

caution advised: combo may incr. risk of serious infection (additive effects)

• emapalumab
Tavneos (avacopan)

+

emapalumab

2 interactions

Caution Advised

avacopan + emapalumab

caution advised: combo may incr. risk of serious infection (additive effects)

• enasidenib
Tavneos (avacopan)

+

enasidenib

1 interaction

Caution Advised

avacopan + enasidenib

caution advised: combo may decr. avacopan levels, efficacy (hepatic metabolism induced)

• epcoritamab
Tavneos (avacopan)

+

epcoritamab

2 interactions

Caution Advised

avacopan + epcoritamab

caution advised: combo may incr. risk of serious infection (additive effects)

• epirubicin
Tavneos (avacopan)

+

epirubicin

1 interaction

Caution Advised

avacopan + epirubicin

caution advised: combo may incr. risk of serious infection (additive effects)

• eribulin
Tavneos (avacopan)

+

eribulin

2 interactions

Caution Advised

avacopan + eribulin

caution advised: combo may incr. risk of serious infection (additive effects)

• erlotinib
Tavneos (avacopan)

+

erlotinib

1 interaction

Caution Advised

avacopan + erlotinib

caution advised: combo may incr. erlotinib levels, risk of adverse effects (hepatic metabolism inhibited)

• eslicarbazepine acetate
Tavneos (avacopan)

+

eslicarbazepine acetate

1 interaction

Caution Advised

avacopan + eslicarbazepine acetate

caution advised: combo may decr. avacopan levels, efficacy (hepatic metabolism induced)

• etanercept
Tavneos (avacopan)

+

etanercept

1 interaction

Caution Advised

avacopan + etanercept

caution advised: combo may incr. risk of serious infection (additive effects)

• etoposide
Tavneos (avacopan)

+

etoposide

1 interaction

Caution Advised

avacopan + etoposide

caution advised: combo may incr. risk of serious infection (additive effects)

• etuvetidigene autotemcel
Tavneos (avacopan)

+

etuvetidigene autotemcel

1 interaction

Caution Advised

avacopan + etuvetidigene autotemcel

caution advised: combo may incr. risk of serious infection (additive effects)

• felbamate
Tavneos (avacopan)

+

felbamate

1 interaction

Caution Advised

avacopan + felbamate

caution advised: combo may decr. avacopan levels, efficacy (hepatic metabolism induced)

• fingolimod
Tavneos (avacopan)

+

fingolimod

1 interaction

Caution Advised

avacopan + fingolimod

caution advised during and x2mo after fingolimod tx: combo may incr. risk of serious infection; infection risk may be prolonged (additive effects)

• floxuridine
Tavneos (avacopan)

+

floxuridine

1 interaction

Caution Advised

avacopan + floxuridine

caution advised: combo may incr. risk of serious infection (additive effects)

• fluconazole
Tavneos (avacopan)

+

fluconazole

1 interaction

Caution Advised

avacopan + fluconazole

caution advised: combo may incr. avacopan levels, risk of adverse effects (hepatic metabolism inhibited)

• fludarabine
Tavneos (avacopan)

+

fludarabine

1 interaction

Caution Advised

avacopan + fludarabine

caution advised: combo may incr. risk of serious infection (additive effects)

• fludrocortisone
Tavneos (avacopan)

+

fludrocortisone

1 interaction

Caution Advised

avacopan + fludrocortisone

caution advised: combo may incr. risk of serious infection (additive effects)

• flunisolide nasal
Tavneos (avacopan)

+

flunisolide nasal

1 interaction

Caution Advised

avacopan + flunisolide nasal

caution advised: combo may incr. risk of serious infection (additive effects)

• fluocinolone intravitreal
Tavneos (avacopan)

+

fluocinolone intravitreal

1 interaction

Caution Advised

avacopan + fluocinolone intravitreal

caution advised: combo may incr. risk of serious infection (additive effects)

• fluorometholone ophthalmic
Tavneos (avacopan)

+

fluorometholone ophthalmic

1 interaction

Caution Advised

avacopan + fluorometholone ophthalmic

caution advised: combo may incr. risk of serious infection (additive effects)

• fluticasone furoate
Tavneos (avacopan)

+

fluticasone furoate

2 interactions

Caution Advised

avacopan + fluticasone furoate

caution advised: combo may incr. risk of serious infection (additive effects)

• fluticasone propionate
Tavneos (avacopan)

+

fluticasone propionate

1 interaction

Caution Advised

avacopan + fluticasone propionate

caution advised: combo may incr. risk of serious infection (additive effects)

• fosamprenavir
Tavneos (avacopan)

+

fosamprenavir

2 interactions

Caution Advised

avacopan + fosamprenavir

caution advised: combo may alter avacopan levels, incr. risk of adverse effects or decr. efficacy (hepatic metabolism altered)

• fruquintinib
Tavneos (avacopan)

+

fruquintinib

1 interaction

Caution Advised

avacopan + fruquintinib

caution advised: combo may incr. risk of serious infection (additive effects)

• garlic
Tavneos (avacopan)

+

garlic

1 interaction

Caution Advised

avacopan + garlic

caution advised w/ supplemental garlic; dietary intake OK: combo may decr. avacopan levels, efficacy (hepatic metabolism induced)

• gemtuzumab ozogamicin
Tavneos (avacopan)

+

gemtuzumab ozogamicin

1 interaction

Caution Advised

avacopan + gemtuzumab ozogamicin

caution advised: combo may incr. risk of serious infection (additive effects)

• ginkgo
Tavneos (avacopan)

+

ginkgo

1 interaction

Caution Advised

avacopan + ginkgo

caution advised: combo may decr. avacopan levels, efficacy (hepatic metabolism induced)

• ginseng, Asian
Tavneos (avacopan)

+

ginseng, Asian

1 interaction

Caution Advised

avacopan + ginseng, Asian

caution advised: combo may decr. avacopan levels, efficacy (hepatic metabolism induced)

• glofitamab
Tavneos (avacopan)

+

glofitamab

1 interaction

Caution Advised

avacopan + glofitamab

caution advised: combo may incr. risk of serious infection (additive effects)

• glycerol phenylbutyrate
Tavneos (avacopan)

+

glycerol phenylbutyrate

1 interaction

Caution Advised

avacopan + glycerol phenylbutyrate

caution advised: combo may decr. avacopan levels, efficacy (hepatic metabolism induced)

• golimumab
Tavneos (avacopan)

+

golimumab

1 interaction

Caution Advised

avacopan + golimumab

caution advised: combo may incr. risk of serious infection (additive effects)

• grapefruit
Tavneos (avacopan)

+

grapefruit

1 interaction

Caution Advised

avacopan + grapefruit

caution advised: combo may incr. avacopan levels, risk of adverse effects (GI metabolism inhibited)

• grazoprevir
Tavneos (avacopan)

+

grazoprevir

1 interaction

Caution Advised

avacopan + grazoprevir

caution advised: combo may incr. grazoprevir levels, risk of adverse effects (hepatic metabolism inhibited)

• griseofulvin
Tavneos (avacopan)

+

griseofulvin

1 interaction

Caution Advised

avacopan + griseofulvin

caution advised: combo may decr. avacopan levels, efficacy (hepatic metabolism induced)

• guselkumab
Tavneos (avacopan)

+

guselkumab

1 interaction

Caution Advised

avacopan + guselkumab

caution advised: combo may incr. risk of serious infection (additive effects)

• hydrocortisone ophthalmic
Tavneos (avacopan)

+

hydrocortisone ophthalmic

1 interaction

Caution Advised

avacopan + hydrocortisone ophthalmic

caution advised: combo may incr. risk of serious infection (additive effects)

• hydroxyurea
Tavneos (avacopan)

+

hydroxyurea

1 interaction

Caution Advised

avacopan + hydroxyurea

caution advised: combo may incr. risk of serious infection (additive effects)

• ibritumomab tiuxetan
Tavneos (avacopan)

+

ibritumomab tiuxetan

1 interaction

Caution Advised

avacopan + ibritumomab tiuxetan

caution advised: combo may incr. risk of serious infection (additive effects)

• icotrokinra
Tavneos (avacopan)

+

icotrokinra

1 interaction

Caution Advised

avacopan + icotrokinra

caution advised: combo may incr. risk of serious infection (additive effects)

• idarubicin
Tavneos (avacopan)

+

idarubicin

1 interaction

Caution Advised

avacopan + idarubicin

caution advised: combo may incr. risk of serious infection (additive effects)

• idecabtagene vicleucel
Tavneos (avacopan)

+

idecabtagene vicleucel

1 interaction

Caution Advised

avacopan + idecabtagene vicleucel

caution advised: combo may incr. risk of serious infection (additive effects)

• ifosfamide
Tavneos (avacopan)

+

ifosfamide

2 interactions

Caution Advised

avacopan + ifosfamide

caution advised: combo may decr. ifosfamide active metabolite levels, efficacy; may incr. risk of serious infection (hepatic metabolism inhibited, decr. active metabolite formation; additive effects)

• imatinib
Tavneos (avacopan)

+

imatinib

1 interaction

Caution Advised

avacopan + imatinib

caution advised: combo may incr. avacopan levels, risk of adverse effects (hepatic metabolism inhibited)

• imlunestrant
Tavneos (avacopan)

+

imlunestrant

2 interactions

Caution Advised

avacopan + imlunestrant

caution advised: combo may incr. imlunestrant levels, risk of adverse effects (hepatic metabolism inhibited)

• inebilizumab
Tavneos (avacopan)

+

inebilizumab

1 interaction

Caution Advised

avacopan + inebilizumab

caution advised: combo may incr. risk of serious infection (additive effects)

• infliximab
Tavneos (avacopan)

+

infliximab

1 interaction

Caution Advised

avacopan + infliximab

caution advised: combo may incr. risk of serious infection (additive effects)

• inotuzumab ozogamicin
Tavneos (avacopan)

+

inotuzumab ozogamicin

1 interaction

Caution Advised

avacopan + inotuzumab ozogamicin

caution advised: combo may incr. risk of serious infection (additive effects)

• iptacopan
Tavneos (avacopan)

+

iptacopan

1 interaction

Caution Advised

avacopan + iptacopan

caution advised: combo may incr. risk of serious infection (additive effects)

• isatuximab
Tavneos (avacopan)

+

isatuximab

1 interaction

Caution Advised

avacopan + isatuximab

caution advised: combo may incr. risk of serious infection (additive effects)

• isavuconazonium
Tavneos (avacopan)

+

isavuconazonium

1 interaction

Caution Advised

avacopan + isavuconazonium

caution advised: combo may incr. levels of both drugs, risk of adverse effects (hepatic metabolism inhibited)

• istradefylline
Tavneos (avacopan)

+

istradefylline

2 interactions

Caution Advised

avacopan + istradefylline

caution advised: combo may incr. istradefylline levels, risk of adverse effects (hepatic metabolism inhibited)

• ixekizumab
Tavneos (avacopan)

+

ixekizumab

1 interaction

Caution Advised

avacopan + ixekizumab

caution advised: combo may incr. risk of serious infection (additive effects)

• lebrikizumab
Tavneos (avacopan)

+

lebrikizumab

2 interactions

Caution Advised

avacopan + lebrikizumab

caution advised: combo may incr. risk of serious infection (additive effects)

• leflunomide
Tavneos (avacopan)

+

leflunomide

1 interaction

Caution Advised

avacopan + leflunomide

caution advised: combo may incr. risk of serious infection (additive effects)

• lenacapavir
Tavneos (avacopan)

+

lenacapavir

2 interactions

Caution Advised

avacopan + lenacapavir

caution advised during and x9mo after lenacapavir tx: combo may incr. avacopan levels, risk of adverse effects (hepatic metabolism inhibited)

• lenalidomide
Tavneos (avacopan)

+

lenalidomide

1 interaction

Caution Advised

avacopan + lenalidomide

caution advised: combo may incr. risk of serious infection (additive effects)

• letermovir
Tavneos (avacopan)

+

letermovir

1 interaction

Caution Advised

avacopan + letermovir

caution advised: combo may incr. avacopan levels, risk of adverse effects (hepatic metabolism inhibited)

• lifileucel
Tavneos (avacopan)

+

lifileucel

1 interaction

Caution Advised

avacopan + lifileucel

caution advised: combo may incr. risk of serious infection (additive effects)

• linvoseltamab
Tavneos (avacopan)

+

linvoseltamab

1 interaction

Caution Advised

avacopan + linvoseltamab

caution advised: combo may incr. risk of serious infection (additive effects)

• lisocabtagene maraleucel
Tavneos (avacopan)

+

lisocabtagene maraleucel

1 interaction

Caution Advised

avacopan + lisocabtagene maraleucel

caution advised: combo may incr. risk of serious infection (additive effects)

• lomustine
Tavneos (avacopan)

+

lomustine

1 interaction

Caution Advised

avacopan + lomustine

caution advised: combo may incr. risk of serious infection (additive effects)

• loncastuximab tesirine
Tavneos (avacopan)

+

loncastuximab tesirine

1 interaction

Caution Advised

avacopan + loncastuximab tesirine

caution advised: combo may incr. risk of serious infection (additive effects)

• loteprednol ophthalmic
Tavneos (avacopan)

+

loteprednol ophthalmic

1 interaction

Caution Advised

avacopan + loteprednol ophthalmic

caution advised: combo may incr. risk of serious infection (additive effects)

• lymphocyte immune globulin, anti-thymocyte globulin
Tavneos (avacopan)

+

lymphocyte immune globulin, anti-thymocyte globulin

2 interactions

Caution Advised

avacopan + lymphocyte immune globulin, anti-thymocyte globulin

caution advised: combo may incr. risk of serious infection (additive effects)

• maraviroc
Tavneos (avacopan)

+

maraviroc

1 interaction

Caution Advised

avacopan + maraviroc

caution advised: combo may incr. maraviroc levels, risk of adverse effects (hepatic metabolism inhibited)

• marnetegragene autotemcel
Tavneos (avacopan)

+

marnetegragene autotemcel

2 interactions

Caution Advised

avacopan + marnetegragene autotemcel

caution advised: combo may incr. risk of serious infection (additive effects)

• melphalan
Tavneos (avacopan)

+

melphalan

1 interaction

Caution Advised

avacopan + melphalan

caution advised: combo may incr. risk of serious infection (additive effects)

• mercaptopurine
Tavneos (avacopan)

+

mercaptopurine

1 interaction

Caution Advised

avacopan + mercaptopurine

caution advised: combo may incr. risk of serious infection (additive effects)

• meropenem
Tavneos (avacopan)

+

meropenem

1 interaction

Caution Advised

avacopan + meropenem

caution advised: combo may decr. avacopan levels, efficacy (hepatic metabolism possibly induced)

• methotrexate
Tavneos (avacopan)

+

methotrexate

1 interaction

Caution Advised

avacopan + methotrexate

caution advised: combo may incr. risk of serious infection (additive effects)

• methylprednisolone
Tavneos (avacopan)

+

methylprednisolone

1 interaction

Caution Advised

avacopan + methylprednisolone

caution advised: combo may incr. methylprednisolone levels, risk of systemic corticosteroid effects including Cushing syndrome and adrenal suppression, serious infection (hepatic metabolism inhibited, additive effects)

• mirikizumab
Tavneos (avacopan)

+

mirikizumab

1 interaction

Caution Advised

avacopan + mirikizumab

caution advised: combo may incr. risk of serious infection (additive effects)

• mitoxantrone
Tavneos (avacopan)

+

mitoxantrone

2 interactions

Caution Advised

avacopan + mitoxantrone

caution advised: combo may incr. risk of serious infection (additive effects)

• mogamulizumab
Tavneos (avacopan)

+

mogamulizumab

1 interaction

Caution Advised

avacopan + mogamulizumab

caution advised: combo may incr. risk of serious infection (additive effects)

• momelotinib
Tavneos (avacopan)

+

momelotinib

1 interaction

Caution Advised

avacopan + momelotinib

caution advised: combo may incr. risk of serious infection (additive effects)

• mometasone implant
Tavneos (avacopan)

+

mometasone implant

1 interaction

Caution Advised

avacopan + mometasone implant

caution advised: combo may incr. risk of serious infection (additive effects)

• mometasone inhaled
Tavneos (avacopan)

+

mometasone inhaled

1 interaction

Caution Advised

avacopan + mometasone inhaled

caution advised: combo may incr. risk of serious infection (additive effects)

• mometasone nasal
Tavneos (avacopan)

+

mometasone nasal

1 interaction

Caution Advised

avacopan + mometasone nasal

caution advised: combo may incr. risk of serious infection (additive effects)

• monomethyl fumarate
Tavneos (avacopan)

+

monomethyl fumarate

1 interaction

Caution Advised

avacopan + monomethyl fumarate

caution advised: combo may incr. risk of serious infection (additive effects)

• mosunetuzumab
Tavneos (avacopan)

+

mosunetuzumab

1 interaction

Caution Advised

avacopan + mosunetuzumab

caution advised: combo may incr. risk of serious infection (additive effects)

• mycophenolate mofetil
Tavneos (avacopan)

+

mycophenolate mofetil

1 interaction

Caution Advised

avacopan + mycophenolate mofetil

caution advised: combo may incr. risk of serious infection (additive effects)

• mycophenolic acid
Tavneos (avacopan)

+

mycophenolic acid

2 interactions

Caution Advised

avacopan + mycophenolic acid

caution advised: combo may incr. risk of serious infection (additive effects)

• nadofaragene firadenovec intravesical
Tavneos (avacopan)

+

nadofaragene firadenovec intravesical

1 interaction

Caution Advised

avacopan + nadofaragene firadenovec intravesical

caution advised: combo may incr. risk of disseminated adenovirus infection (immunosuppressive effects)

• naldemedine
Tavneos (avacopan)

+

naldemedine

1 interaction

Caution Advised

avacopan + naldemedine

caution advised: combo may incr. naldemedine levels, risk of adverse effects (hepatic metabolism inhibited)

• narsoplimab
Tavneos (avacopan)

+

narsoplimab

1 interaction

Caution Advised

avacopan + narsoplimab

caution advised: combo may incr. risk of serious infection (additive effects)

• nelarabine
Tavneos (avacopan)

+

nelarabine

1 interaction

Caution Advised

avacopan + nelarabine

caution advised: combo may incr. risk of serious infection (additive effects)

• nevirapine
Tavneos (avacopan)

+

nevirapine

1 interaction

Caution Advised

avacopan + nevirapine

caution advised: combo may decr. avacopan levels, efficacy (hepatic metabolism induced)

• nipocalimab
Tavneos (avacopan)

+

nipocalimab

1 interaction

Caution Advised

avacopan + nipocalimab

caution advised: combo may incr. risk of serious infection (additive effects)

• obecabtagene autoleucel
Tavneos (avacopan)

+

obecabtagene autoleucel

1 interaction

Caution Advised

avacopan + obecabtagene autoleucel

caution advised: combo may incr. risk of serious infection (additive effects)

• obinutuzumab
Tavneos (avacopan)

+

obinutuzumab

1 interaction

Caution Advised

avacopan + obinutuzumab

caution advised: combo may incr. risk of serious infection (additive effects)

• ocrelizumab
Tavneos (avacopan)

+

ocrelizumab

2 interactions

Caution Advised

avacopan + ocrelizumab

caution advised: combo may incr. risk of serious infection (additive effects)

• odevixibat
Tavneos (avacopan)

+

odevixibat

1 interaction

Caution Advised

avacopan + odevixibat

caution advised: combo may decr. avacopan levels, efficacy (hepatic metabolism induced)

• ofatumumab
Tavneos (avacopan)

+

ofatumumab

1 interaction

Caution Advised

avacopan + ofatumumab

caution advised: combo may incr. risk of serious infection (additive effects)

• olutasidenib
Tavneos (avacopan)

+

olutasidenib

2 interactions

Caution Advised

avacopan + olutasidenib

caution advised: combo may decr. avacopan levels, efficacy (hepatic metabolism possibly induced)

• ospemifene
Tavneos (avacopan)

+

ospemifene

1 interaction

Caution Advised

avacopan + ospemifene

caution advised: combo may incr. ospemifene levels, risk of adverse effects (hepatic metabolism inhibited)

• oxaliplatin
Tavneos (avacopan)

+

oxaliplatin

2 interactions

Caution Advised

avacopan + oxaliplatin

caution advised: combo may incr. risk of serious infection (additive effects)

• oxcarbazepine
Tavneos (avacopan)

+

oxcarbazepine

1 interaction

Caution Advised

avacopan + oxcarbazepine

caution advised: combo may decr. avacopan levels, efficacy (hepatic metabolism induced)

• ozanimod
Tavneos (avacopan)

+

ozanimod

1 interaction

Caution Advised

avacopan + ozanimod

caution advised during and x3mo after ozanimod tx: combo may incr. risk of serious infection; infection risk may be prolonged (additive effects)

• paclitaxel
Tavneos (avacopan)

+

paclitaxel

1 interaction

Caution Advised

avacopan + paclitaxel

caution advised: combo may incr. risk of serious infection (additive effects)

• pegcetacoplan
Tavneos (avacopan)

+

pegcetacoplan

1 interaction

Caution Advised

avacopan + pegcetacoplan

caution advised: combo may incr. risk of serious infection (additive effects)

• pentostatin
Tavneos (avacopan)

+

pentostatin

1 interaction

Caution Advised

avacopan + pentostatin

caution advised: combo may incr. risk of serious infection (additive effects)

• perampanel
Tavneos (avacopan)

+

perampanel

1 interaction

Caution Advised

avacopan + perampanel

caution advised if on perampanel 12 mg/day: combo may decr. avacopan levels, efficacy (hepatic metabolism induced)

• pioglitazone
Tavneos (avacopan)

+

pioglitazone

1 interaction

Caution Advised

avacopan + pioglitazone

caution advised: combo may decr. avacopan levels, efficacy (hepatic metabolism induced)

• pivekimab sunirine
Tavneos (avacopan)

+

pivekimab sunirine

1 interaction

Caution Advised

avacopan + pivekimab sunirine

caution advised: combo may incr. alkylating agent (FGN849) levels, risk of adverse effects (hepatic metabolism inhibited)

• polatuzumab vedotin
Tavneos (avacopan)

+

polatuzumab vedotin

1 interaction

Caution Advised

avacopan + polatuzumab vedotin

caution advised: combo may incr. risk of serious infection (additive effects)

• pomalidomide
Tavneos (avacopan)

+

pomalidomide

1 interaction

Caution Advised

avacopan + pomalidomide

caution advised: combo may incr. risk of serious infection (additive effects)

• ponesimod
Tavneos (avacopan)

+

ponesimod

1 interaction

Caution Advised

avacopan + ponesimod

caution advised during and x1-2wk after ponesimod tx: combo may incr. risk of serious infection; infection risk may be prolonged (additive effects)

• pozelimab
Tavneos (avacopan)

+

pozelimab

1 interaction

Caution Advised

avacopan + pozelimab

caution advised: combo may incr. risk of serious infection (additive effects)

• prednisolone
Tavneos (avacopan)

+

prednisolone

1 interaction

Caution Advised

avacopan + prednisolone

caution advised: combo may incr. risk of serious infection (additive effects)

• prednisolone ophthalmic
Tavneos (avacopan)

+

prednisolone ophthalmic

1 interaction

Caution Advised

avacopan + prednisolone ophthalmic

caution advised: combo may incr. risk of serious infection (additive effects)

• prednisone
Tavneos (avacopan)

+

prednisone

2 interactions

Caution Advised

avacopan + prednisone

caution advised: combo may decr. avacopan levels, efficacy; may incr. risk of serious infection (hepatic metabolism induced; additive effects)

• procarbazine
Tavneos (avacopan)

+

procarbazine

1 interaction

Caution Advised

avacopan + procarbazine

caution advised: combo may incr. risk of serious infection (additive effects)

• ravulizumab
Tavneos (avacopan)

+

ravulizumab

1 interaction

Caution Advised

avacopan + ravulizumab

caution advised: combo may incr. risk of serious infection (additive effects)

• regorafenib
Tavneos (avacopan)

+

regorafenib

1 interaction

Caution Advised

avacopan + regorafenib

caution advised: combo may incr. risk of serious infection (additive effects)

• rilonacept
Tavneos (avacopan)

+

rilonacept

1 interaction

Caution Advised

avacopan + rilonacept

caution advised: combo may incr. risk of serious infection (additive effects)

• risankizumab
Tavneos (avacopan)

+

risankizumab

1 interaction

Caution Advised

avacopan + risankizumab

caution advised: combo may incr. risk of serious infection (additive effects)

• ritlecitinib
Tavneos (avacopan)

+

ritlecitinib

1 interaction

Caution Advised

avacopan + ritlecitinib

caution advised: combo may incr. risk of serious infection (additive effects)

• rituximab
Tavneos (avacopan)

+

rituximab

2 interactions

Caution Advised

avacopan + rituximab

caution advised: combo may incr. risk of serious infection (additive effects)

• roflumilast
Tavneos (avacopan)

+

roflumilast

1 interaction

Caution Advised

avacopan + roflumilast

caution advised: combo may incr. roflumilast levels, risk of adverse effects (hepatic metabolism inhibited)

• roflumilast topical
Tavneos (avacopan)

+

roflumilast topical

2 interactions

Caution Advised

avacopan + roflumilast topical

caution advised: combo may incr. roflumilast levels, risk of adverse effects (hepatic metabolism inhibited)

• romidepsin
Tavneos (avacopan)

+

romidepsin

1 interaction

Caution Advised

avacopan + romidepsin

caution advised: combo may incr. risk of serious infection (additive effects)

• ropeginterferon alfa-2b
Tavneos (avacopan)

+

ropeginterferon alfa-2b

2 interactions

Caution Advised

avacopan + ropeginterferon alfa-2b

caution advised: combo may incr. risk of serious infection (additive effects)

• rozanolixizumab
Tavneos (avacopan)

+

rozanolixizumab

1 interaction

Caution Advised

avacopan + rozanolixizumab

caution advised: combo may incr. risk of serious infection (additive effects)

• rufinamide
Tavneos (avacopan)

+

rufinamide

1 interaction

Caution Advised

avacopan + rufinamide

caution advised: combo may decr. avacopan levels, efficacy (hepatic metabolism induced)

• sarilumab
Tavneos (avacopan)

+

sarilumab

1 interaction

Caution Advised

avacopan + sarilumab

caution advised: combo may decr. avacopan levels, efficacy; may incr. risk of serious infection (hepatic metabolism altered; sarilumab may reverse inflammatory cytokine-induced downregulation of CYP450 enzymes resulting in relative induction of enzymes upon tx start and downregulation upon D/C; additive effects)

• satralizumab
Tavneos (avacopan)

+

satralizumab

1 interaction

Caution Advised

avacopan + satralizumab

caution advised: combo may incr. risk of serious infection (additive effects)

• secukinumab
Tavneos (avacopan)

+

secukinumab

1 interaction

Caution Advised

avacopan + secukinumab

caution advised: combo may incr. risk of serious infection (additive effects)

• seladelpar
Tavneos (avacopan)

+

seladelpar

1 interaction

Caution Advised

avacopan + seladelpar

caution advised if CYP2C9 poor metabolizer or if also combined w/ moderate CYP2C9 inhibitor: combo may incr. seladelpar levels, risk of adverse effects (hepatic metabolism inhibited)

• selinexor
Tavneos (avacopan)

+

selinexor

1 interaction

Caution Advised

avacopan + selinexor

caution advised: combo may incr. risk of serious infection (additive effects)

• sevabertinib
Tavneos (avacopan)

+

sevabertinib

1 interaction

Caution Advised

avacopan + sevabertinib

caution advised: combo may incr. sevabertinib levels, risk of adverse effects (hepatic metabolism inhibited)

• sibeprenlimab
Tavneos (avacopan)

+

sibeprenlimab

1 interaction

Caution Advised

avacopan + sibeprenlimab

caution advised: combo may incr. risk of serious infection (additive effects)

• silodosin
Tavneos (avacopan)

+

silodosin

1 interaction

Caution Advised

avacopan + silodosin

caution advised: combo may incr. silodosin levels, risk of adverse effects (hepatic metabolism inhibited)

• siltuximab
Tavneos (avacopan)

+

siltuximab

1 interaction

Caution Advised

avacopan + siltuximab

caution advised: combo may incr. risk of serious infection (additive effects)

• sirolimus topical
Tavneos (avacopan)

+

sirolimus topical

1 interaction

Caution Advised

avacopan + sirolimus topical

caution advised: combo may incr. sirolimus levels, risk of adverse effects (hepatic metabolism inhibited)

• spesolimab
Tavneos (avacopan)

+

spesolimab

2 interactions

Caution Advised

avacopan + spesolimab

caution advised: combo may incr. risk of serious infection (additive effects)

• stiripentol
Tavneos (avacopan)

+

stiripentol

1 interaction

Caution Advised

avacopan + stiripentol

caution advised: combo may decr. avacopan levels, efficacy (hepatic metabolism possibly induced)

• sulfasalazine
Tavneos (avacopan)

+

sulfasalazine

2 interactions

Caution Advised

avacopan + sulfasalazine

caution advised: combo may incr. risk of serious infection (additive effects)

• sunvozertinib
Tavneos (avacopan)

+

sunvozertinib

1 interaction

Caution Advised

avacopan + sunvozertinib

caution advised: combo may decr. avacopan levels, efficacy (hepatic metabolism induced)

• sutimlimab
Tavneos (avacopan)

+

sutimlimab

1 interaction

Caution Advised

avacopan + sutimlimab

caution advised: combo may incr. risk of serious infection (additive effects)

• tafasitamab
Tavneos (avacopan)

+

tafasitamab

1 interaction

Caution Advised

avacopan + tafasitamab

caution advised: combo may incr. risk of serious infection (additive effects)

• talquetamab
Tavneos (avacopan)

+

talquetamab

1 interaction

Caution Advised

avacopan + talquetamab

caution advised: combo may incr. risk of serious infection (additive effects)

• tarlatamab
Tavneos (avacopan)

+

tarlatamab

1 interaction

Caution Advised

avacopan + tarlatamab

caution advised: combo may incr. risk of serious infection (additive effects)

• teclistamab
Tavneos (avacopan)

+

teclistamab

1 interaction

Caution Advised

avacopan + teclistamab

caution advised: combo may incr. risk of serious infection (additive effects)

• tecovirimat
Tavneos (avacopan)

+

tecovirimat

1 interaction

Caution Advised

avacopan + tecovirimat

caution advised: combo may decr. avacopan levels, efficacy (hepatic metabolism induced)

• telotristat ethyl
Tavneos (avacopan)

+

telotristat ethyl

1 interaction

Caution Advised

avacopan + telotristat ethyl

caution advised: combo may decr. avacopan levels, efficacy (hepatic metabolism induced)

• temozolomide
Tavneos (avacopan)

+

temozolomide

1 interaction

Caution Advised

avacopan + temozolomide

caution advised: combo may incr. risk of serious infection (additive effects)

• teplizumab
Tavneos (avacopan)

+

teplizumab

1 interaction

Caution Advised

avacopan + teplizumab

caution advised: combo may incr. risk of serious infection (additive effects)

• teriflunomide
Tavneos (avacopan)

+

teriflunomide

2 interactions

Caution Advised

avacopan + teriflunomide

caution advised: combo may incr. risk of serious infection (additive effects)

• thioguanine
Tavneos (avacopan)

+

thioguanine

1 interaction

Caution Advised

avacopan + thioguanine

caution advised: combo may incr. risk of serious infection (additive effects)

• thiotepa
Tavneos (avacopan)

+

thiotepa

1 interaction

Caution Advised

avacopan + thiotepa

caution advised: combo may incr. risk of serious infection (additive effects)

• ticagrelor
Tavneos (avacopan)

+

ticagrelor

1 interaction

Caution Advised

avacopan + ticagrelor

caution advised: combo may incr. ticagrelor levels, risk of dyspnea, bleeding, other adverse effects (hepatic metabolism inhibited)

• tildrakizumab
Tavneos (avacopan)

+

tildrakizumab

1 interaction

Caution Advised

avacopan + tildrakizumab

caution advised: combo may incr. risk of serious infection (additive effects)

• tisagenlecleucel
Tavneos (avacopan)

+

tisagenlecleucel

1 interaction

Caution Advised

avacopan + tisagenlecleucel

caution advised: combo may incr. risk of serious infection (additive effects)

• tocilizumab
Tavneos (avacopan)

+

tocilizumab

1 interaction

Caution Advised

avacopan + tocilizumab

caution advised: combo may decr. avacopan levels, efficacy; may incr. risk of serious infection (hepatic metabolism altered; tocilizumab may reverse inflammatory cytokine-induced downregulation of CYP450 enzymes resulting in relative induction of enzymes; additive effects)

• topiramate
Tavneos (avacopan)

+

topiramate

1 interaction

Caution Advised

avacopan + topiramate

caution advised especially w/ topiramate doses >200 mg/day: combo may decr. avacopan levels, efficacy (hepatic metabolism induced)

• topotecan
Tavneos (avacopan)

+

topotecan

1 interaction

Caution Advised

avacopan + topotecan

caution advised: combo may incr. risk of serious infection (additive effects)

• tovorafenib
Tavneos (avacopan)

+

tovorafenib

1 interaction

Caution Advised

avacopan + tovorafenib

caution advised: combo may decr. avacopan levels, efficacy (hepatic metabolism induced)

• tralokinumab
Tavneos (avacopan)

+

tralokinumab

1 interaction

Caution Advised

avacopan + tralokinumab

caution advised: combo may incr. risk of serious infection (additive effects)

• tretinoin
Tavneos (avacopan)

+

tretinoin

1 interaction

Caution Advised

avacopan + tretinoin

caution advised: combo may incr. tretinoin levels, risk of adverse effects (hepatic metabolism inhibited)

• triamcinolone
Tavneos (avacopan)

+

triamcinolone

1 interaction

Caution Advised

avacopan + triamcinolone

caution advised: combo may incr. risk of serious infection (additive effects)

• tuberculin purified protein derivative
Tavneos (avacopan)

+

tuberculin purified protein derivative

1 interaction

Caution Advised

avacopan + tuberculin purified protein derivative

caution advised during and x5-6wk after avacopan tx: combo may interfere with test results (antagonistic effects)

• ublituximab
Tavneos (avacopan)

+

ublituximab

1 interaction

Caution Advised

avacopan + ublituximab

caution advised: combo may incr. risk of serious infection (additive effects)

• upadacitinib
Tavneos (avacopan)

+

upadacitinib

1 interaction

Caution Advised

avacopan + upadacitinib

caution advised: combo may incr. upadacitinib levels, risk of serious infection, myelosuppression, other adverse effects (hepatic metabolism inhibited, additive effects)

• ustekinumab
Tavneos (avacopan)

+

ustekinumab

1 interaction

Caution Advised

avacopan + ustekinumab

caution advised: combo may incr. risk of serious infection (additive effects)

• vaborbactam
Tavneos (avacopan)

+

vaborbactam

1 interaction

Caution Advised

avacopan + vaborbactam

caution advised: combo may decr. avacopan levels, efficacy (hepatic metabolism possibly induced)

• vamorolone
Tavneos (avacopan)

+

vamorolone

1 interaction

Caution Advised

avacopan + vamorolone

caution advised: combo may decr. avacopan levels, efficacy; may incr. risk of serious infection (hepatic metabolism possibly induced; additive effects)

• vedolizumab
Tavneos (avacopan)

+

vedolizumab

1 interaction

Caution Advised

avacopan + vedolizumab

caution advised: combo may incr. risk of serious infection (additive effects)

• verapamil
Tavneos (avacopan)

+

verapamil

1 interaction

Caution Advised

avacopan + verapamil

caution advised: combo may incr. levels of both drugs, risk of hypotension, bradycardia, AV block, other adverse effects (hepatic metabolism inhibited)

• vilazodone
Tavneos (avacopan)

+

vilazodone

1 interaction

Caution Advised

avacopan + vilazodone

caution advised: combo may incr. vilazodone levels, risk of adverse effects (hepatic metabolism inhibited)

• vilobelimab
Tavneos (avacopan)

+

vilobelimab

1 interaction

Caution Advised

avacopan + vilobelimab

caution advised: combo may incr. risk of serious infection (additive effects)

• vorasidenib
Tavneos (avacopan)

+

vorasidenib

1 interaction

Caution Advised

avacopan + vorasidenib

caution advised: combo may decr. avacopan levels, efficacy (hepatic metabolism possibly induced)

• vusolimogene oderparepvec
Tavneos (avacopan)

+

vusolimogene oderparepvec

1 interaction

Caution Advised

avacopan + vusolimogene oderparepvec

caution advised: combo may incr. risk of disseminated herpetic infection, may decr. immune response (immunosuppressive effects)

• zilucoplan
Tavneos (avacopan)

+

zilucoplan

1 interaction

Caution Advised

avacopan + zilucoplan

caution advised: combo may incr. risk of serious infection (additive effects)